New macrocyclic compounds and derivatives as EGFR inhibitors

Fourth-generation EGFR TKIs address the limitations of current treatments by potently inhibiting complex EGFR mutations, enhancing treatment efficacy and reducing toxicity in NSCLC patients.

JP7590996B2Active Publication Date: 2024-11-27BOEHRINGER INGELHEIM INT GMBH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021576576
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-24
Filing Date
2020-06-23
Publication Date
2024-11-27
Estimated Expiration
2040-06-23

AI Technical Summary

Technical Problem

Current EGFR tyrosine kinase inhibitors (TKIs) are ineffective against the EGFR del19/L858R T790M C797S mutant allele, leading to rapid relapse in non-small cell lung cancer (NSCLC) patients, and there is a lack of effective treatments for secondary and tertiary resistance mutations.

Method used

Development of fourth-generation EGFR TKIs that potently inhibit EGFR del19 or L858R variants, including T790M and C797S mutations, with high selectivity across the human kinome and brain penetration, reducing on-target toxicity and resistance.

Benefits of technology

The fourth-generation EGFR TKIs effectively target NSCLC tumors with complex EGFR mutations, extending treatment duration and reducing adverse effects, offering therapeutic options for patients resistant to earlier generations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590996000001
    Figure 0007590996000001
  • Figure 0007590996000002
    Figure 0007590996000002
  • Figure 0007590996000003
    Figure 0007590996000003
Patent Text Reader

Abstract

The present invention encompasses compounds of formula (I), their use as inhibitors of mutant EGFR, pharmaceutical compositions containing such compounds, and their use as medicaments / pharmaceutical uses, especially as agents for treating and / or preventing neoplastic diseases. TIFF2022538228000159.tif3669 (where the group R 1 From R 3 , A, B and L and p and q have the meanings given in the claims and the specification.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [ka] (In the formula, the group R 1 From R 3 , A, B and L and p and q have the meanings indicated in the claims and the description), their use as inhibitors of mutated EGFR, pharmaceutical compositions containing such compounds and their use as medicines / pharmaceutical uses, especially as agents for treating and / or preventing neoplastic diseases. [Background technology]

[0002] The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that transmits mitogenic signals. Mutations in the EGFR gene are found in approximately 12%–47% of non-small cell lung cancer (NSCLC) tumors with adenocarcinoma histology (Midha, 2015). The two most frequent EGFR alterations found in NSCLC tumors are a short in-frame deletion (del19) within exon 19 of the EGFR gene and a single missense mutation L858R in exon 21 (Konduri, 2016). These two mutations cause ligand-independent EGFR activation and are collectively referred to as EGFR M+. Del19 and L858R mutations in EGFR sensitize NSCLC tumors to treatment with EGFR tyrosine kinase inhibitors (TKIs). Clinical experience has shown response rates of approximately 60-85% in EGFR M+ NSCLC patients treated in the first-line with the first-, second-, and third-generation EGFR TKIs erlotinib, gefitinib, afatinib, and osimertinib (Mitsudomi, 2010; Park, 2016; Soria, 2017; Zhou, 2011). These responses demonstrate that EGFR M+ NSCLC cells and tumors are dependent on oncogenic EGFR activity for viability and proliferation, thus establishing del19 or L858R mutant EGFR as a valid drug target and predictive biomarker for treating NSCLC. The first-generation EGFR TKIs erlotinib and gefitinib and the second-generation TKI afatinib are FDA approved for the first-line treatment of patients with EGFR M+ NSCLC.

[0003] Tumor responses are accompanied by significant tumor shrinkage in patients, but the responses are usually short-lived, with most patients relapsing within 10-12 months of treatment with first- and second-generation EGFR TKIs (Mitsudomi, 2010;Park, 2016;Soria, 2017;Zhou, 2011). The most prominent molecular mechanism underlying progression is the acquisition of a secondary mutation in EGFR, namely T790M, in 50%-70% of patients who progress on first- and second-generation EGFR inhibitors (Blakely, 2012;Kobayashi, 2005). This mutation weakens the inhibitory activity of first- and second-generation TKIs in cellular assays (see data in Table 16). Mutation-selective and covalent third-generation EGFR TKIs, such as osimertinib, have been developed, which efficiently inhibit primary EGFR mutations del19 and L858R, with or without secondary T790M resistance mutations (Cross, 2014;Wang, 2016). The recently demonstrated efficacy of the third-generation EGFR TKI osimertinib in second-line treatment of EGFR M+T790M-positive NSCLC clinically demonstrates that tumor cell viability and proliferation are dependent on the mutant EGFR allele (Janne, 2015;Mok, 2016). Approximately 70% of EGFR M+T790M-positive patients previously treated with earlier generation EGFR TKIs responded to second-line osimertinib treatment. However, disease progression occurs after a mean period of 10 months (Mok, 2016). The mechanisms underlying acquired resistance to third-generation EGFR TKIs are being studied in small cohorts of patients and are beginning to emerge (Ou, 2017). Recent data suggest that one of the main resistance mechanisms is the acquisition of the tertiary EGFR mutation C797S, which relapses with osimertinib TKI in approximately 20-40% of second-line patients (Ortiz-Cuaran, 2016; Ou, 2017; Song, 2016; Thress, 2015; Yu, 2015). Third-generation TKIs, such as osimertinib, covalently attach to EGFR via residue C797 (Cross, 2014; Wang, 2016). In cellular models, the C797S mutation abolishes the activity of tested third-generation TKIs (Thress, 2015) (see data in Table 16). In second-line patients, the mutation C797S was preferentially found together with the EGFR del19 genotype and in the same allele as the T790M mutation (in cis configuration) (82% of C797S+ patients) (Piotrowska, 2017).Importantly, EGFR del19 / L858R T790M C797S cis-mutation kinase variants that emerge in second-line patients who progress on osimertinib (Ortiz-Cuaran, 2016; Ou, 2017; Song, 2016; Thress, 2015; Yu, 2015) can no longer be inhibited by first-, second- or third-generation EGFR TKIs (Thress, 2015) (see data in Table 16). Based on the fact that the C797S mutation has been detected in patients with progression on osimertinib (Ortiz-Cuaran, 2016;Ou, 2017;Song, 2016;Thress, 2015;Yu, 2015), it is believed that tumor cell viability and proliferation in EGFR del19 / L858R T790M C797S patients depends on this mutant allele and can be inhibited by targeting this allele.Further EGFR resistance mutations with lower incidence than C797S: L718Q, L792F / H / Y and C797G / N, have recently been described in second-line EGFR M+NSCLC patients who progressed on osimertinib (Bersanelli, 2016;Chen, 2017;Ou, 2017).

[0004] The third-generation EGFR TKI osimertinib has also recently shown efficacy in previously untreated EGFR M+ NSCLC patients (Soria, 2017). Disease progression occurs after a median time of 19 months. The EGFR resistance mutation spectrum after first-line osimertinib treatment has yet to be more extensively studied, but the first available data also suggest the emergence of the mutation C797S, which abrogates osimertinib activity (Ramalingam, 2017).

[0005] The fact that approved EGFR TKIs cannot inhibit the EGFR del19 / L858R T790M C797S variant, an allele that arises after a patient's progression on second-line osimertinib treatment, highlights the medical need for next-generation EGFR TKIs, "fourth-generation EGFR TKIs," which should potently inhibit EGFR del19 or L858R, regardless of the presence of two common resistance mutations, T790M and C797S, especially EGFR del19 T790M C797S. The utility of such fourth-generation EGFR TKIs is enhanced by the activity of the compounds against additional resistance mutations, such as the potential osimertinib resistance mutations C797X (X=S, G, N) and L792F / H / Y. The broad activity of the molecule against EGFR del19 or L858R variants without T790M and / or C797S mutations also ensures that the new compound can efficiently address the expected allelic complex in the patient's tumor as a monotherapy agent. To promote efficacy of administration and to reduce EGFR-mediated on-target toxicity, the fourth generation EGFR TKI should not inhibit wild-type EGFR. High selectivity across the human kinome reduces the off-target toxicity of the compound. Another desirable property of the fourth generation EGFR TKI is the ability to efficiently penetrate the brain (blood-brain barrier penetration) so that brain metastases and leptomeningeal disease can be treated. Finally, the fourth generation EGFR TKI should present a reduced propensity for resistance compared to existing EGFR TKIs to increase the duration of response in patients.

[0006] The aforementioned properties of the fourth-generation EGFR TKIs allow for the treatment of patients who progress on second-line treatment with third-generation TKIs, such as osimertinib (e.g., with genotype EGFR del19 / L858R T790M C797S), and patients have a currently untargeted therapeutic treatment option. Furthermore, these properties also have the potential to allow the fourth-generation EGFR TKIs to prolong the duration of response in patients on initial treatment lines, such as patients who progress on first-line osimertinib treatment for EGFR C797S mutation, as well as in first-line patients. The activity of the fourth-generation EGFR TKIs against resistance mutations, such as T790M, C797X (X=S, G, N) and L792X (X=F, H, Y), has the potential to delay the onset of resistance through EGFR within target mutations in NSCLC tumors. The properties outlined above define the 4th generation EGFR TKI as the first EGFR TKI that can efficiently target patients with NSCLC tumors harboring EGFR del19 / L858R T790M C797X / L792X variants. Furthermore, the 4th generation EGFR TKI is the first C797X-active compound that also inhibits T790M-positive alleles possessing EGFR wild-type sparing activity and efficiently penetrates the brain.

[0007] The aforementioned properties have not been achieved by any previously described EGFR inhibitor compound. In the past few years, selective targeting of mutant EGFR has been receiving increasing attention. To date, several attempts have been made to identify and optimize inhibitors that target the catalytic site of EGFR mutations or the allosteric site of EGFR protein, but with limited success in terms of the above-mentioned properties. Recently, several EGFR inhibitors have been published that can overcome EGFR resistance mutations, including the T790M mutation, as well as the C797S mutation, and a combination of both (Zhang, 2017;Park, 2017;Chen, 2017;Bryan 2016;Juchum, 2017;Gunther, 2017;WO2017 / 004383).The majority of the published molecules are non-covalent variants of quinazoline based second generation EGFR inhibitors (Patel, 2017;Park, 2017;Chen, 2017). However, these published molecules are either weak inhibitors with lower selectivity than EGFR wt (Patel, 2017; Chen, 2017) or were designed to bind specifically only to del19 / T790M / C797S mutations without activity against other EGFR variant combinations and mutations (Park, 2017). Other published classes of compounds show activity only against T790M and T790M / C797S resistance mutations in the context of L858R activation (Bryan 2016; Juchum, 2017; Gunther, 2017). However, because these mutations and mutation combinations are only observed in a fraction of the patient population, and because allelic complexes are often abundant in metastatic tumors, it is highly unlikely that they will meet the essential criteria for development into effective EGFR inhibitors.

[0008] The following prior art documents disclose non-covalent compounds as mutation-selective EGFR inhibitors with activity against EGFR with T790M: WO2014 / 210354, WO2014 / 081718, Heald, 2015; Hanan, 2014; Lelais, 2016; Chan, 2016. Although the compounds from the literature mentioned above are claimed to be active against the two most common EGFR activating / resistant mutation combinations del19 / T790M and L858 / T790M, most of them only show weak activity against the more frequent del19 / T790M mutation, and do not show affinity for EGFR with only the primary activating mutations del19 and L858R. Such selective inhibition of double mutant EGFR over activity against single activating mutations is highly undesirable and would cause limited efficacy due to the heterogeneity of EGFR mutations in patients. Moreover, most of the compounds show only a little selectivity against EGFR wt, which is known to be the main cause of the side effects (diarrhea, skin rash) that cause target-specific toxicity common in EGFR targeted therapy. This specific cytotoxic component is undesirable because it potentially causes adverse events in treated patients.

[0009] The following prior art documents disclose aminobenzimidazole-based compounds as EGFR selective inhibitors with activity against both oncogenic driver mutations L858R and del19, as well as against the T790M resistance mutation and their combination: WO2013 / 184757, WO2013 / 184766, WO2015 / 143148, WO2015 / 143161, WO2016 / 185333, Lelais, 2016; Jia, 2016. The following prior art documents disclose further aminobenzimidazole-based compounds: WO2003 / 030902, WO2003 / 041708, WO2004 / 014369, WO2004 / 014905, WO2005 / 079791, WO2007 / 133983, WO2012 / 018668, WO2014 / 036016, WO 2014 / 121942, WO2016 / 176473, WO2017 / 049068, WO2017 / 049069. Summary of the Invention

[0010] Some of the compounds (I) according to the present invention have such an aminobenzimidazole scaffold as a basic structure, but these published prior art compounds do not contain a macrocycle. Aminobenzimidazoles as part of a macrocycle have been disclosed in WO2014 / 121942 as IRAK inhibitors, but they only show weak inhibitory activity against EGFR mutants (see data in Table 16). In addition, structurally related previously published aminobenzimidazoles have been designed as covalent EGFR inhibitors with a reactive (head) group on the molecule. The activity of these inhibitors is most driven by covalent binding to the C797 residue of the EGFR protein, and thus depends on the reactive group. This results in high sensitivity to the C797S resistance mutation (Engel, 2016). However, the corresponding compounds without the reactive (head) group derived from these prior art aminobenzimidazoles show only weak residual activity against EGFR mutations (see data in Table 16). This makes the compound ineffective as a non-covalent EGFR inhibitor and limits its use as a broad-spectrum EGFR mutation inhibitor. Thus, against this background, those skilled in the art would not consider the previously known aminobenzimidazole scaffolds to be a promising starting point for identifying EGFR inhibitors with the profile of fourth generation EGFR inhibitors as previously defined herein.

[0011] None of the aforementioned published compounds exhibit the desired properties for an effective and clinically relevant inhibitor targeting EGFR resistance mutations. In summary, compound (I) according to the present invention shows broad activity against EGFR del19 or EGFR L858R variants with or without T790M and / or C797S mutations, which ensures that the compound can efficiently address the expected allelic complex in patients' tumors as a monotherapy agent. To facilitate the efficacy of administration and to reduce EGFR-mediated on-target toxicity, the compound according to the present invention has a reduced inhibitory capacity against wild-type EGFR. Compound (I) shows high selectivity across the human kinome, which can reduce the off-target toxicity of the compound. Another property of compound (I) according to the present invention is its potential brain penetration (blood-brain barrier penetration) so that it can be used to treat brain metastasis and leptomeningeal disease. In addition to inhibitory effect and potency, the compounds disclosed herein show good solubility and finely tuned DMPK properties.

[0012] References TIFF0007590996000002.tif99153 TIFF0007590996000003.tif189138 TIFF0007590996000004.tif189137 TIFF0007590996000005.tif151139 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] compound Surprisingly, the group R 1 From R 3 It has now been found that the compounds of formula (I), in which A, B and L, and p and q have the meanings given below, act as inhibitors of mutant EGFR, which is involved in the control of cell proliferation. Thus, the compounds according to the invention can be used for example to treat diseases characterized by excessive or abnormal cell proliferation.

[0014] The present invention therefore relates to compounds of formula (I) or a salt thereof. [ka] (In the formula, [A0]

[0015] [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 0, 1, 2 and 3; Each R 1 is R a1 and R b1 are independently selected from the group consisting of: R a1 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R b1 and / or R c1 may be substituted with Each R b1 -OR c1 , -NR c1 R c1 , halogen, -CN, -C(O)R c1 , -C(O)OR c1 , -C(O)NR c1 R c1 , -S(O)2R c1 , -S(O)NR c1 R c1 , -NHC(O)R c1 , -N(C1-4 Alkyl)C(O)R c1 , -NHC(O)OR c1 , -N(C 1-4 Alkyl)C(O)OR c1 and the divalent substituent =O, Each R c1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R d1 and / or R e1 may be substituted with Each R d1 -OR e1 , -NR e1 R e1 , halogen, -CN, -C(O)R e1 , -C(O)OR e1 , -C(O)NR e1 R e1 , -S(O)2R e1 , -S(O)NR e1 R e1 , -NHC(O)R e1 , -N(C 1-4 Alkyl)C(O)R e1 , -NHC(O)OR e1 , -N(C 1-4 Alkyl)C(O)OR e1 and the divalent substituent =O, Each R e1 is hydrogen, C1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, C 1-4 3-10 membered heterocyclyl optionally substituted with alkyl, C 1-4 Alkoxy-C 1-4 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl and (C 1-4 Alkyl)2amino-C 1-4 independently selected from the group consisting of alkyl, [B0]

[0016] [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; q is selected from the group consisting of 0, 1 and 2; Each R 2 is C 1-4 Alkyl, C 1-4 Haloalkyl, -CN, C 1-4 Alkoxy, C 1-4 independently selected from the group consisting of haloalkoxy and halogen; [C0] R 3 is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen, -CN, -NH2, -NH(C 1-4 alkyl) and -N(C 1-4 alkyl)2; [D0] L is linear C 3-7 Alkylene, linear C 3-7 Alkenylene and Linear C 3-7 alkynylene, such linear C 3-7 Alkylene, linear C 3-7 Alkenylene and Linear C 3-7In the alkynylene, one or two methylene groups -CH2- can be replaced by oxygen, -NH- and -N(C 1-4 alkyl)-, Such a linear chain is represented by the carbon atom C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; One carbon atom, two carbon atoms or one carbon atom and one nitrogen atom in such a straight chain may be C 1-5 It may be bridged with an alkylene, such bridge C 1-5 One methylene group -CH2- in the alkylene is replaced by oxygen, resulting in C 3-6 may form a carbocyclic ring or a 3- to 6-membered nitrogen- and / or oxygen-containing heterocyclic ring)

[0017] In one aspect [A1], the present invention provides a method for producing a composition comprising: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But R a1 and R b1 are independently selected from the group consisting of: R a1 But, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R b1 and / or R c1 may be substituted with Each R b1 But -OR c1 , -NRc1 R c1 , halogen, -CN, -C(O)R c1 , -C(O)OR c1 , -C(O)NR c1 R c1 and the divalent substituent =O, Each R c1 But hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R d1 and / or R e1 may be substituted with Each R d1 But -OR e1 , -NR e1 R e1 , halogen, -CN, -C(O)R e1 , -C(O)OR e1 , -C(O)NR e1 R e1 and the divalent substituent =O, Each R e1 But hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, C 1-4 3-10 membered heterocyclyl optionally substituted with alkyl, C 1-4 Alkoxy-C 1-4 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl and (C 1-4 Alkyl)2amino-C 1-4 or a salt thereof, wherein the aryl group is independently selected from the group consisting of alkyl, aryl, aryl and aryl.

[0018] In another aspect [A2], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But R a1 and R b1 are independently selected from the group consisting of: R a1 But, C 1-6 selected from the group consisting of alkyl and 3-10 membered heterocyclyl; 1-6 All alkyl and 3- to 10-membered heterocyclyl groups may be one or more of the same or different R b1 and / or R c1 may be substituted with Each R b1 But -OR c1 , -NR c1 R c1 , halogen, -CN, -C(O)R c1 , -C(O)OR c1 , -C(O)NR c1 R c1 and the divalent substituent =O, Each R c1 But hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl and 3- to 10-membered heterocyclyl; 1-6 Alkyl, C 3-10 Cycloalkyl and 3- to 10-membered heterocyclyl are each independently selected from one or more of the same or different R d1 and / or R e1 may be substituted with Each R d1 But -OR e1 , -NR e1 R e1 , halogen, -CN, -C(O)R e1 , -C(O)OR e1 , -C(O)NR e1 R e1 and the divalent substituent =O, Each R e1 But hydrogen, C 1-6 Alkyl, C 3-10Cycloalkyl, C 1-4 3-10 membered heterocyclyl optionally substituted with alkyl, C 1-4 Alkoxy-C 1-4 Alkyl and (C 1-4 Alkyl)2amino-C 1-4 or a salt thereof, wherein the aryl group is independently selected from the group consisting of alkyl, aryl, aryl and aryl.

[0019] In another aspect [A3], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But (a), (b), (c) and (d): (a)-(O) n -(CH2) m -A(in the formula, A is C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkoxy-C 1-4 Alkyl, -C(O)OC 1-4 Alkyl, -C(O)-C 1-4 Alkyl, C 3-6 Cycloalkyl, -NH(C 1-4 alkyl), -N(C 1-4 is a 3- to 11-membered heterocyclyl optionally substituted with one or more identical or different substituents selected from the group consisting of alkyl)2 and the divalent substituent =O; n is 0 or 1, m is selected from the group consisting of 0, 1 and 2; (b)-NR A R A (In the formula, Each R A is hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy-C 1-4 C substituted with alkyl, 4-7 membered heterocyclyl 1-4 Alkyl, (C1-4 Alkyl)2amino-C 1-4 Alkyl and (C 1-4 Alkyl)2amino-C 1-4 Alkoxy-C 1-4 alkyl), (c)-N(C 1-4 alkyl)2, -NH(C 1-4 alkyl), -C(O)NH-C 1-4 Alkyl, -C(O)-heterocyclyl with 5- to 7-membered heterocyclyl, -OH, -CN and -C(O)OC 1-4 C, optionally substituted with a substituent selected from the group consisting of alkyl 1-6 Alkyl, (d)-OC 1-6 Alkyl, -C(O)NH-C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)OC 1-6 Alkyl, -CN, halogen and C 1-6 -C(O)-heterocyclyl with 5- to 7-membered heterocyclyl optionally substituted with alkyl or a salt thereof, independently selected from the group consisting of:

[0020] In another aspect [A4], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But (a), (c), and (d): (a)-(O) n -(CH2) m -A(in the formula, A is a set of one or more identical or different C 1-4 3- to 11-membered heterocyclyl optionally substituted by alkyl; n is 0 or 1, m is selected from the group consisting of 0, 1 and 2; (c)-N(C 1-4 alkyl)2 and -NH(C 1-4 C, optionally substituted with a substituent selected from the group consisting of alkyl 1-6 Alkyl, (d)-OC 1-6 Alkyl, -C(O)NH-C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)OC 1-6 Alkyl, halogen and C 1-6 -C(O)-heterocyclyl with 5- to 7-membered heterocyclyl optionally substituted with alkyl or a salt thereof, independently selected from the group consisting of:

[0021] In another aspect [A5], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But -(O) n -(CH2) m -A, A is a binary combination of one or more identical or different C 1-4 3- to 11-membered heterocyclyl optionally substituted by alkyl; n is 0 or 1; wherein m is selected from the group consisting of 0, 1 and 2; or a salt thereof.

[0022] In another aspect [A6], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 1, 2 and 3; Each R 1 But halogen, C 1-4Alkyl, C 1-4 Alkoxy, C 1-4 Heterocyclyl-C with 5- to 7-membered heterocyclyl optionally substituted with alkyl 1-4 Alkoxy, C 1-4 Heterocyclyl-C with 5- to 7-membered heterocyclyl optionally substituted with alkyl 1-4 Alkyl, C 1-4 5- to 7-membered heterocyclyl optionally substituted with alkyl, (C 1-4 Alkyl)2N-C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, C 1-4 -C(O)-heterocyclyl and -C(O)OC, optionally substituted with alkyl, 5- to 7-membered heterocyclyl 1-4 or a salt thereof, wherein R is selected from the group consisting of alkyl;

[0023] In another aspect [A7], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; The compound of formula (I) or a salt thereof, wherein p is 0.

[0024] In further aspects [A8], [A9], [A10], [A11], [A12], [A13] and [A14], the present invention relates to a method for producing a composition comprising the steps of: [ka] but, [ka] is selected from the group consisting of R 1 and p is as defined in any one of the embodiments [A0], [A1], [A2], [A3], [A4], [A5] or [A6], or a salt thereof.

[0025] In another aspect [A15], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof.

[0026] In another aspect [A16], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof.

[0027] In further aspects [A17], [A18], [A19], [A20], [A21], [A22] and [A23], the present invention relates to a method for producing a composition comprising the steps of: [ka] but, [ka] and R 1 is as defined in any one of the embodiments [A0], [A1], [A2], [A3], [A4], [A5] or [A6], or a salt thereof.

[0028] In further aspects [A24], [A25], [A26], [A27], [A28], [A29] and [A30], the present invention relates to a method for producing a composition comprising the steps of: [ka] but, [ka] and R 1 is as defined in any one of the embodiments [A0], [A1], [A2], [A3], [A4], [A5] or [A6], or a salt thereof.

[0029] In another aspect [A31], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof.

[0030] In another aspect [A32], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof, wherein the compound is selected from the group consisting of:

[0031] In another aspect [B1], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; The compound of formula (I) or a salt thereof, wherein q is 0.

[0032] In another aspect [B2], the present invention provides a method for producing a composition comprising the steps of: [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; q is 1, R 2 But, C 1-4 or a salt thereof, wherein R is selected from the group consisting of alkyl and halogen.

[0033] In further aspects [B3], [B4] and [B5], the present invention provides a method for producing a method for the preparation of a compound comprising the steps of: [ka] but, [ka] is selected from the group consisting of R 2 and q is as defined in any one of the embodiments [B0], [B1] or [B2], or a salt thereof.

[0034] In another aspect [B6], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof.

[0035] In another aspect [B7], the present invention provides a method for producing a composition comprising: [ka] but, [ka] or a salt thereof.

[0036] In another aspect [B8], the present invention provides a method for producing a composition comprising the steps of: [ka] but, [ka] or a salt thereof.

[0037] In another aspect [C1], the present invention provides a compound comprising R 3 But hydrogen, C 1-4 or a salt thereof, wherein the alkyl group is selected from the group consisting of alkyl, halogen and -CN. In another aspect [C2], the present invention provides a compound comprising R 3 is hydrogen or a salt thereof. In another aspect [C3], the present invention provides a compound comprising R 3 is -CN, or a salt thereof.

[0038] In another aspect [C4], the present invention provides a compound comprising R 3 C 1-4 The present invention relates to a compound of formula (I) or a salt thereof, wherein In another aspect [C5], the present invention provides a compound comprising R 3 is methyl, or a salt thereof. In another aspect [C6], the present invention provides a compound comprising R 3 is halogen, preferably chlorine or fluorine, or a salt thereof.

[0039] In another aspect [D1], the present invention provides a method for producing a composition comprising the steps of: L is linear C 3-7 Alkylene, such a linear C 3-7 In the alkylene, one or two methylene groups -CH2- can be replaced by oxygen, -NH- and -N(C 1-4 alkyl)-, Such a linear chain is represented by the carbon atom C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; One carbon atom, two carbon atoms or one carbon atom and one nitrogen atom in such a straight chain may be C 1-5 It may be bridged with an alkylene, such bridge C 1-5 One methylene group -CH2- in the alkylene is replaced by oxygen, resulting in C 3-6 The present invention relates to a compound of formula (I) or a salt thereof, which may form a carbocyclic ring or a 3- to 6-membered nitrogen- and / or oxygen-containing heterocyclic ring.

[0040] In another aspect [D2], the present invention provides a method for producing a composition comprising the steps of: L is linear C 3-7 is alkylene, Linear C 3-7 Alkylene is C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; Linear C 3-7 One or two carbon atoms in the alkylene are C 1-5 Bridged with alkylene to form C 3-6 The present invention relates to a compound of formula (I) or a salt thereof, which may form a carbocyclic ring.

[0041] In another aspect [D3], the present invention provides a method for producing a composition comprising the steps of: L is selected from the group consisting of linear C4 alkylene, linear C5 alkylene, linear C6 alkylene, and linear C7 alkylene; Linear C4 alkylene, linear C5 alkylene, linear C6 alkylene and linear C7 alkylene are 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; In such linear C4 alkylene, linear C5 alkylene, linear C6 alkylene and linear C7 alkylene, one or two carbon atoms are 1-5 Bridged with alkylene to form C 3-6 The present invention relates to a compound of formula (I) or a salt thereof, which may form a carbocyclic ring.

[0042] In another aspect [D4], the present invention provides a method for producing a composition comprising the steps of: L, [ka] or a salt thereof, wherein the compound is selected from the group consisting of:

[0043] The structural aspects [A1] to [A32], [B1] to [B8], [C1] to [C6], and [D1] to [D4] described above are all preferred embodiments of the corresponding aspects [A0], [B0], [C0], and [D0], respectively. The structural aspects [A0] to [A32], [B0] to [B8], [C0] to [C6], and [D0] to [D4] related to different molecular parts of the compound (I) according to the invention can be combined with each other as desired in combinations [A][B][C][D] to obtain the preferred compound (I). Each combination [A][B][C][D] represents and defines an individual embodiment or a general subset of the compound (I) according to the invention. Preferred embodiments of the present invention having structure (I) are any of exemplary compounds I-1 to I-57 and subsets thereof. All synthetic intermediates and their salts, both generally defined and specifically disclosed herein, are also part of the present invention. All individual synthetic reaction steps, as well as the reaction sequences comprising these individual synthetic reaction steps, are both generally defined or specifically disclosed herein and are also part of the present invention.

[0044] The present invention further relates to hydrates, solvates, polymorphs, metabolites, derivatives, isomers and prodrugs of the compounds of formula (I) (including all individual embodiments and general subsets disclosed herein). The present invention further relates to tautomers of the compounds of formula (I), including all individual embodiments and general subsets disclosed herein.

[0045] Specifically, compounds of formula (I) may exist in any of the following tautomeric forms A, B and C, all of which are intended to be elements of the present invention and all of which are within the scope of formula (I): [ka] shall be covered by The present invention further relates to hydrates of compounds of formula (I), including all individual embodiments and general subsets disclosed herein. The present invention further relates to solvates of the compounds of formula (I), including all individual embodiments and general subsets disclosed herein. For example, compounds of formula (I) bearing ester groups (including all individual embodiments and general subsets disclosed herein) are potential prodrugs, where the ester is cleaved under physiological conditions, and are also part of the present invention. The present invention further relates to pharma- ceutically acceptable salts of the compounds of formula (I), including all individual embodiments and generic subsets disclosed herein. The present invention further relates to pharma- ceutically acceptable salts of the compounds of formula (I) (including all individual embodiments and general subsets disclosed herein) with inorganic or organic acids or bases.

[0046] Medicinal Uses - Methods of Treatment The present invention is directed inter alia to compounds of formula (I) (including all individual embodiments and general subsets disclosed herein) that are useful for the treatment and / or prevention of diseases and / or conditions associated with or modulated by mutant EGFR, in which inhibition of mutant EGFR is of therapeutic benefit, including, but not limited to, the treatment and / or prevention of cancer. In one aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use as a pharmaceutical. In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use in a method of treatment of the human or animal body. In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of diseases and / or conditions in which inhibition of mutant EGFR would be of therapeutic benefit, including, but not limited to, the treatment and / or prevention of cancer. In another aspect, the present invention relates to an SOS1 inhibitor compound, particularly a compound of formula (I), or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of cancer. In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use in a method of treating and / or preventing cancer in the human or animal body.

[0047] In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of cancer. In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for use in a method of treating and / or preventing cancer in the human or animal body.

[0048] In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) or a pharma- ceutically acceptable salt thereof, for use as defined herein, wherein said compound is administered before, after, or together with at least one other pharmacologically active agent. In another aspect, the present invention relates to a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) or a pharma- ceutically acceptable salt thereof, for use as defined herein, wherein said compound is administered in combination with at least one other pharmacologically active agent. In another aspect, the invention relates to a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) or a pharma- ceutically acceptable salt thereof, for use in a method of treatment or in a method of treatment as defined herein. In another aspect, the present invention relates to the use of a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for treating and / or preventing cancer. In another aspect, the present invention relates to the use of a compound of formula (I) as defined herein (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, wherein said compound is administered before, after, or together with at least one other pharmacologically active agent.

[0049] In another aspect, the invention relates to the use of a compound of formula (I) as defined herein (including all individual embodiments and generic subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, for treatment. In another aspect, the invention relates to a method of treating and / or preventing diseases and / or conditions in which inhibition of mutant EGFR would be of therapeutic benefit, comprising the step of administering to a human a therapeutically effective amount of a compound of Formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof. In another aspect, the invention relates to a method of treating and / or preventing cancer, comprising the step of administering to a human a therapeutically effective amount of a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof. In another aspect, the present invention relates to a method as defined herein, wherein a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, is administered before, after, or together with at least one other pharmacologically active agent. In another aspect, the present invention relates to a method as defined herein, wherein a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) or a pharma- ceutically acceptable salt thereof is administered in combination with a therapeutically effective amount of at least one other pharmacologically active agent. In another aspect, the invention relates to a method for treating as defined herein.

[0050] In another aspect, the present invention provides a method for producing a composition comprising: a first pharmaceutical composition or dosage form comprising a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) and optionally comprising one or more pharma- ceutically acceptable carriers, excipients and / or vehicles; and A kit comprising at least a second pharmaceutical composition or dosage form which comprises another pharmacologically active agent and which may comprise one or more pharma- ceutically acceptable carriers, excipients and / or vehicles. In another aspect, the present invention relates to a pharmaceutical composition comprising at least one (preferably one) compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients. In another aspect, the invention relates to a pharmaceutical preparation comprising a compound of formula (I) (including all individual embodiments and general subsets disclosed herein), or a pharma- ceutically acceptable salt thereof, and at least one (preferably one) other pharmacologically active agent.

[0051] In one aspect, the disease / condition / cancer to be treated / prevented with the compounds of formula (I) (including all individual embodiments and general subsets disclosed herein) or with the pharmaceutical uses, methods of use, treatment and / or prevention defined herein is selected from the group consisting of lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial cancer, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer and mesothelioma, including metastases (particularly brain metastases) of all of the cancers listed. In another aspect, the disease / condition / cancer treated / prevented by the compound of formula (I) (including all individual embodiments and general subsets disclosed herein) or by the pharmaceutical use, use, treatment and / or prevention method defined herein is lung cancer.Preferably, the lung cancer treated is non-small cell lung cancer (NSCLC), including, for example, locally advanced or metastatic NSCLC, NSCLC adenocarcinoma, squamous NSCLC and non-squamous NSCLC.Most preferably, the lung cancer treated is NSCLC adenocarcinoma.

[0052] In another aspect, the disease / condition / cancer to be treated / prevented with the compounds of formula (I) (including all individual embodiments and general subsets disclosed herein) or with the pharmaceutical uses, methods of use, treatment and / or prevention defined herein is a disease / condition / cancer, preferably cancer (including all embodiments disclosed herein), in which the EGFR genotype is selected from genotypes 1 to 16 according to Table A (del19=exon 19 deletion, specifically e.g. delE746_A750 (most common), delE746_S752insV, delL747_A750insP, delL747_P753insS and delS752_I759).

[0053] [Table 1] Thus, in one aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR del19 genotype.Preferably, the cancer patient to be treated and suffering from a cancer with EGFR del19 genotype is administered a compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a first-line treatment, i.e., the patient is treatment-naive to EGFR TKI. In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR del19 T790M genotype.Preferably, the cancer patient to be treated and suffering from the cancer with EGFR del19 T790M genotype is administered the compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on first-line treatment with a first or second generation EGFR TKI (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib).

[0054] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with EGFR del19 C797S genotype.Preferably, the cancer patient to be treated and suffering from the cancer with EGFR del19 C797S genotype is administered the compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on first-line treatment with third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010). In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR del19 C797X (preferably C797G or C797N) genotype.Preferably, the cancer patient to be treated and suffering from the cancer with EGFR del19 C797X (preferably C797G or C797N) genotype is administered the compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on first-line treatment with third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010).

[0055] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with EGFR del19 T790M C797S genotype.Preferably, the cancer patient to be treated and suffering from cancer with EGFR del19 T790M C797S genotype is administered the compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third-line treatment, i.e., the patient progresses on first-line treatment with first or second-generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) when T790M is acquired, and progresses on second-line treatment with third-generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) when C797S is acquired. In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with the EGFR del19 T790M C797X (preferably C797G or C797N) genotype. Preferably, cancer patients who are treated and suffer from cancer with the EGFR del19 T790M C797X (preferably C797G or C797N) genotype are administered a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third-line treatment, i.e., the patient progresses on first-line treatment with a first or second generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) if they acquire T790M, and progresses on second-line treatment with a third generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) if they acquire C797X (preferably C797G or C797N).

[0056] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with EGFR del19 L792X (preferably L792F, L792H or L792Y) genotype.Preferably, the cancer patient to be treated and suffering from the cancer with EGFR del 19 L792X (preferably L792F, L792H or L792Y) genotype is administered the compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on first-line treatment with third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010).

[0057] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with the EGFR del19 T790M L792X (preferably L792F, L792H or L792Y) genotype. Preferably, cancer patients who are treated and suffer from cancer with an EGFR del19 T790M L792X (preferably L792F, L792H or L792Y) genotype are administered a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third-line treatment, i.e., the patient progresses on first-line treatment with a first or second generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) if they acquire T790M, and progresses on second-line treatment with a third generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) if they acquire L792X (preferably L792F, L792H or L792Y).

[0058] In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with the EGFR L858R genotype.Preferably, the cancer patient to be treated and suffering from the cancer with the EGFR L858R genotype is administered a compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a first-line treatment, i.e., the patient is treatment-naive to an EGFR TKI. In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR L858R T790M genotype.Preferably, the cancer patient to be treated and suffering from a cancer with EGFR L858R T790M genotype is administered a compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on a first-line treatment with a first or second generation EGFR TKI (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib). In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR L858R C797S genotype.Preferably, the cancer patient to be treated and suffering from a cancer with EGFR L858R C797S genotype is administered a compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on a first-line treatment with a third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010).

[0059] In another aspect, the cancer to be treated (including all of the embodiments disclosed herein) is a cancer with EGFR L858R C797X (preferably C797G or C797N) genotype.Preferably, the cancer patient to be treated and suffering from a cancer with EGFR L858R C797X (preferably C797G or C797N) genotype is administered a compound of formula (I) (including all of the individual embodiments and general subsets disclosed herein) as a second-line treatment, i.e., the patient progresses on a first-line treatment with a third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010). In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with EGFR L858R T790M C797S genotype.Preferably, the cancer patient to be treated and suffering from cancer with EGFR L858R T790M C797S genotype is administered the compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third-line treatment, i.e., the patient progresses on first-line treatment with first or second-generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) when T790M is acquired, and progresses on second-line treatment with third-generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) when C797S is acquired.

[0060] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with the EGFR L858R T790M C797X (preferably C797G or C797N) genotype. Preferably, cancer patients who are treated and suffer from cancer having an EGFR L858R T790M C797X (preferably C797G or C797N) genotype are administered a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third line treatment, i.e., the patient progresses on first line treatment with a first or second generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) if they acquire T790M, and progresses on second line treatment with a third generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) if they acquire C797X (preferably C797G or C797N). In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with EGFR L858R L792X (preferably L792F, L792H or L792Y) genotype.Preferably, the cancer patient to be treated and suffering from a cancer with EGFR L858R L792X (preferably L792F, L792H or L792Y) genotype is administered a compound of formula (I) administered as a second-line treatment, i.e., the patient progresses on a first-line treatment with a third-generation EGFR TKI (i.e., treatment with osimertinib, olmutinib, nazartinib or AC0010).

[0061] In another aspect, the cancer to be treated (including all embodiments disclosed herein) is a cancer with the EGFR L858R T790M L792X (preferably L792F, L792H or L792Y) genotype. Preferably, cancer patients suffering from cancer who are treated and have an EGFR L858R T790M L792X (preferably L792F, L792H or L792Y) genotype are administered a compound of formula (I) (including all individual embodiments and general subsets disclosed herein) as a third line treatment, i.e., the patient progresses on first line treatment with a first or second generation EGFR TKI (i.e. treatment with gefitinib, erlotinib, afatinib or dacomitinib) if they acquire T790M, and progresses on second line treatment with a third generation EGFR TKI (i.e. treatment with osimertinib, olmutinib, nazartinib or AC0010) if they acquire L792X (preferably L792F, L792H or L792Y).

[0062] In another aspect, the pharmacologically active agent used with / in combination with the compounds of formula (I) (including all individual embodiments and general subsets disclosed herein) or for use in the pharmaceutical uses, methods of use, treatment and / or prevention defined herein may be selected from any one or more of the following (preferably there is only one additional pharmacologically active agent used in all of these embodiments): 1. EGFR and / or its mutant inhibitors a.EGFR TKIs, such as afatinib, erlotinib, gefitinib, lapatinib, dacomitinib, osimertinib, olmutinib, nazartinib, AC0010. b. EGFR antibodies, e.g. cetuximab, panitumumab, necitumumab. 2. Inhibitors of MEK and / or its mutants For example, trametinib, cobimetinib, binimetinib, selumetinib, and refametinib. 3. Inhibitors of c-MET and / or its mutants a.For example, savolitinib, cabozantinib, foretinib. b. MET antibodies, e.g. emibetuzumab. 4. Mitotic kinase inhibitors a. For example, CDK4 / 6 inhibitors i. For example, palbociclib, ribociclib, abemaciclib. 5. Immunotherapy a. For example, immune checkpoint inhibitors i. For example, anti-CTLA4 mAb, anti-PD1 mAb, anti-PD-L1 mAb, anti-PD-L2 mAb, anti-LAG3 mAb, anti-TIM3 mAb. ii. Anti-PD1 mAbs are preferred. iii. For example, ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilizumab, PDR-001 (BAP049-clone-E as disclosed and used in WO2017 / 019896). b. For example, immunomodulatory agents i. For example, a CD73 inhibitor or a CD73 inhibitor antibody 6. Antiangiogenic Agents a.For example, bevacizumab, nintedanib. 7. Apoptosis inducers a. For example, Bcl-2 inhibitors i. For example, venetoclax, obatoclax, navitoclax. b. For example, Mcl-1 inhibitors i.For example AZD-5991, AMG-176, S-64315. 8. mTOR inhibitors a. For example, rapamycin, temsirolimus, everolimus, ridaforolimus. 9. Histone deacetylase inhibitors 10.IL6 Inhibitors 11.JAK Inhibitors

[0063] Other pharmacologically active substances which may be used in combination with compound (I) according to the invention (including all individual embodiments and general subsets disclosed herein) are, for example, state of the art or standard of care compounds, such as cell proliferation inhibitors, antiangiogenic agents, steroids or immunomodulators / checkpoint inhibitors.

[0064] Further examples of pharmacologically active substances which may be administered in combination with the compound (I) according to the invention (including all individual embodiments and general subsets disclosed herein) are hormones, hormone analogs and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g. goserelin acetate, luprolide), growth factors and / or their corresponding receptors (growth factors, e.g. platelet-derived growth factor (PDGF), fibroblast growth factor (F ... GF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), human epidermal growth factor (HER, e.g. HER2, HER3, HER4), and hepatocyte growth factor (HGF) and / or their corresponding receptors), inhibitors such as (anti-)growth factor antibodies, (anti-)growth factor receptor antibodies and tyrosine kinase inhibitors, e.g. cetuximab, gefitinib, afatinib, nintedanib, imatinib, lapatinib, bosutinib, bevacizumab and trastuzumab); antimetabolites (e.g. antifolates, e.g. methotrexate, raltitrexed, pyrimidine analogues, e.g. 5-fluorouracil (5-FU), ribonucleoside and deoxyribonucleoside analogues, capecitabine and gemcitabine, purine and adenosine analogues, e.g. mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (ara C), fludarabine); antitumor antibiotics (e.g. anthracyclins, e.g. doxorubicin, doxil (pegylated liposomal doxorubicin hydrochloride, myocet (non-pegylated liposomal doxorubicin), daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin,streptozocin; platinum derivatives (e.g. cisplatin, oxaliplatin, carboplatin); alkylating agents (e.g. estramustine, mechlorethamine, melphalan, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas, e.g. carmustin and lomustin, thiotepa); antimitotic agents (e.g. vinca alkaloids, e.g. vinblastine, vindesine, sin), vinorelbine and vincristine; and taxanes, e.g. paclitaxel, docetaxel; angiogenesis inhibitors (e.g. tasquinimod), tubulin inhibitors; DNA synthesis inhibitors, PARP inhibitors, topoisomerase inhibitors (e.g. epipodophyllotoxins, e.g. etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantrone), serine / threonine kinase inhibitors (e.g. PDK1 inhibitors, Raf inhibitors, A- Raf inhibitors, B-Raf inhibitors, C-Raf inhibitors, mTOR inhibitors, mTORC1 / 2 inhibitors, PI3K inhibitors, PI3Kα inhibitors, dual mTOR / PI3K inhibitors, STK33 inhibitors, AKT inhibitors, PLK1 inhibitors, inhibitors of CDK, Aurora kinase inhibitors), tyrosine kinase inhibitors (e.g. PTK2 / FAK inhibitors), protein protein interaction inhibitors (e.g. IAP activators, Mcl-1, MDM2 / MDMX), MEK inhibitors, ERK inhibitors, FLT3 inhibitors, BRD4 inhibitors, IGF-1R inhibitors, TRAILR2 inhibitors Agonists, Bcl-xL inhibitors, Bcl-2 inhibitors, Bcl-2 / Bcl-xL inhibitors, ErbB receptor inhibitors, BCR-ABL inhibitors, ABL inhibitors, Src inhibitors, rapamycin analogues (e.g. everolimus, temsirolimus, ridaforolimus, sirolimus), androgen synthesis inhibitors, androgen receptor inhibitors, DNMT inhibitors, HDAC inhibitors, ANG1 / 2 inhibitors, CYP17 inhibitors, radiopharmaceuticals, proteasome inhibitors, immunotherapeutic agents such as immune checkpoint inhibitors (e.g. CTLA4, PD1, PD-L1, PD-L2,LAG3 and TIM3 binding molecules / immunoglobulins, e.g., ipilimumab, nivolumab, pembrolizumab), ADCC (antibody-dependent cell-mediated cytotoxicity) enhancers (e.g., anti-CD33 antibodies, anti-CD37 antibodies, anti-CD20 antibodies), t-cell engagers (e.g., bispecific T-cell engagers (BiTE®), e.g., CD3×BCMA, CD3×CD33, CD3×CD19, PSMA×CD3), tumor vaccines, and various chemotherapeutic agents, e.g., amifostin, anagrelid, clodronat, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole, mesna, mitotane, pamidronate, and porfimer,

[0065] Any of the diseases / conditions / cancers, pharmaceutical uses, methods of use, treatment and / or prevention (including molecular characteristics / genetic characteristics / genotypes) disclosed or defined herein may be treated / carried out with any of the compounds of formula (I) disclosed or defined herein (including all individual embodiments and general subsets disclosed herein).

[0066] formulation Suitable preparations for administering the compound (I) of the present invention will be clear to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, liquids, in particular solutions for injection (sc, iv, im) and solutions for injection (injections), elixirs, syrups, sachets, emulsions, inhalants or dispersible powders. The content of the medicament active compound should be in the range of 0.1-90% by weight, preferably 0.5-50% by weight, of the composition as a whole, i.e., an amount sufficient to achieve the dosage ranges specified below. The doses specified can be given several times a day, if necessary.

[0067] Suitable tablets can be obtained, for example, by mixing the active substance of the invention with known excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants. Tablets can also comprise several layers. Coated tablets can therefore be prepared by coating cores produced similarly to tablets with substances commonly used for tablet coating, such as collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or to prevent incompatibilities, the core can also consist of several layers. Similarly, tablet coatings can consist of several layers, optionally to achieve delayed release using the excipients mentioned above for tablets.

[0068] Syrups or elixirs containing the active substances or combinations thereof according to the invention may further contain sweeteners, such as saccharine, cyclamate, glycerol or sugar, and flavour enhancers, such as flavours, for example vanillin or orange extract. They may also contain suspension adjuvants or thickeners, such as sodium carboxymethylcellulose, wetting agents, such as condensation products of fatty alcohols with ethylene oxide, or preservatives, such as p-hydroxybenzoates. Solutions for infusion and injection are prepared in the usual manner, for example with the addition of isotonicity agents, preservatives, e.g. p-hydroxybenzoates, or stabilizers, e.g. alkali metal salts of ethylenediaminetetraacetic acid, and may use emulsifying and / or dispersing agents, but when water is used as diluent, for example organic solvents may be used as solvating agents or solubilizing aids, and may be transferred into injection vials or ampoules or injection bottles. Capsules containing one or more active substances, or a combination of active substances, can be prepared, for example, by mixing the active substances with an inert carrier, such as lactose or sorbitol, and packing them into gelatin capsules.

[0069] Suitable suppositories can be prepared, for example, by mixing with carriers provided for this purpose, such as neutral fats, or polyethylene glycol, or derivatives thereof. Excipients that may be used include, for example, water, pharma- ceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), vegetable oils (e.g., arachis or sesame oil), monofunctional or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural inorganic powders (e.g., kaolin, clay, talc, chalk), synthetic inorganic powders (e.g., highly disperse silicic acid and silicates), sugars (e.g., sucrose, lactose and glucose), emulsifiers (e.g., lignin, spent sulfite liquor, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g., magnesium stearate, talc, stearic acid and sodium lauryl sulfate). The preparation is administered by conventional methods, preferably by oral or transdermal route, most preferably by oral route.For oral administration, apart from the above-mentioned carriers, tablets can of course contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate, together with various additives such as starch, preferably potato starch, gelatin.In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc can be used at the same time as the tableting process.In the case of aqueous suspension, the active substance can be combined with various flavor enhancers or colorants in addition to the excipients mentioned above. For parenteral use, a solution of the agent and a suitable liquid carrier may be used. The applicable daily dose range of the compound of formula (I) is usually 1 mg to 2000 mg, preferably 1 to 1000 mg. Dosages for intravenous use are from 1 mg to 1000 mg at various injection rates, preferably from 5 mg to 500 mg at various injection rates. However, deviations from the amounts specified may be necessary depending on the body weight, age, route of administration, severity of the disease, individual response to the drug, nature of the formulation, and the time or interval at which the drug is administered (continuous or intermittent treatment with one or more doses per day). Thus, in some cases, the use of less than the minimum dose indicated above may be sufficient, while in other cases the upper limit may have to be exceeded. When administering larger amounts, it may be appropriate to divide them into several smaller doses throughout the day.

[0070] The following formulation examples illustrate the present invention but do not limit its scope. Examples of pharmaceutical preparations A) Per tablet 100 mg of active substance according to formula (I) Lactose 140mg Corn starch 240mg Polyvinylpyrrolidone 15mg Magnesium stearate 5mg 500mg

[0071] The finely ground active ingredient, lactose and part of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size. B) Per tablet 80 mg of active ingredient according to formula (I) Lactose 55mg Corn starch 190mg Microcrystalline cellulose 35mg Polyvinylpyrrolidone 15mg Sodium carboxymethyl starch 23mg Magnesium stearate 2mg 400mg

[0072] The finely ground active ingredient, a portion of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved, and the remaining corn starch and water are treated to form granules, which are dried and sieved. Sodium carboxymethyl starch and magnesium stearate are added, mixed, and the mixture is compressed to form tablets of suitable size. C) Per tablet 25 mg of active substance according to formula (I) Lactose 50mg Microcrystalline cellulose 24mg Magnesium stearate 1mg 100mg The active ingredient, lactose and cellulose are mixed together. The mixture is screened, then moistened with water, kneaded, wet granulated, dried or dry granulated, or directly final blended with magnesium stearate, and compressed into tablets of suitable shape and size. When wet granulated, additional lactose or cellulose and magnesium stearate are added, and the mixture is compressed to produce tablets of suitable shape and size. D) Ampoules solution 50 mg of active substance according to formula (I) Sodium chloride 50mg Water for injection: 5mL The active substance is dissolved in water at its own pH or at a pH that may be 5.5-6.5, and sodium chloride is added to make it isotonic. The resulting solution is filtered to be pyrogen-free, and the filtrate is transferred under aseptic conditions into ampoules, which are then sterilized and melt-sealed. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

[0073] definition Terms not specifically defined herein should be given the meaning that could be given to the term by one of ordinary skill in the art in light of the disclosure and the context. However, as used herein, unless otherwise indicated, the following terms have the meanings indicated and the following conventions are observed. Prefix C, where x and y each represent positive integers (x < y). x-y The use of x-y is specifically and directly related and indicates that the chain or ring structure so identified or referred to, or the combination of chains and ring structures as a whole, can consist of carbon atoms with the maximum value of y and the minimum value of x. The indication of the number of members in a group containing one or more heteroatoms (e.g., heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl) relates to the total number of atoms of all ring members or the total number of all ring and carbon chain members.

[0074] The indication of the number of carbon atoms in a group consisting of a combination of a carbon chain and a carbon ring structure (e.g., cycloalkylalkyl, arylalkyl) relates to the total number of carbon atoms of all carbon rings and carbon chain members. Clearly, the ring structure has at least three members. Generally, in a group containing two or more sub - groups (e.g., heteroarylalkyl, heterocyclylalkyl, cycloalkylalkyl, arylalkyl), the last - named sub - group is the radical attachment point. For example, the substituent aryl - C 1-6 Alkyl is C 1-6 Alkyl group bonded to an aryl group, and C 1-6 The alkyl group is bonded to the nucleus or group to which the substituent is attached.

[0075] For groups such as HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, those skilled in the art can determine the radical attachment point to the molecule from the free valence of the group itself. Alkyl represents a monovalent saturated hydrocarbon chain that can exist in both straight - chain (unbranched) and branched forms. When alkyl is substituted, the substitution can occur independently of each other by mono - substitution or multi - substitution on all carbon atoms bearing hydrogen in each case. "C 1-5The term "alkyl" includes, for example, HC-, HC-CH-, HC-CH-CH-, HC-CH(CH)-, HC-CH-CH-CH-, HC-CH(CH)-, HC-CH(CH)-CH-, HC-C(CH)-, HC-CH-CH-CH-CH-, HC-CH(CH)-CH-, HC-C(CH)-, HC-CH-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH(CH)-CH-, HC-CH-CH(CH)-CH-, HC-CH-CH-CH-, HC-CH-C(CH)-, HC-C(CH)-CH-, HC-CH(CH)-CH-, HC-CH-CH(CH)-CH- and HC-CH-CH(CHCH)-. Further examples of alkyl are methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-propyl, n-Pr, -CH2CH2CH3), 2-propyl (i-Pr, isopropyl, -CH(CH3)2), 1-butyl (n-butyl, n-Bu, -CH2CH2CH2CH3), 2-methyl-1-propyl (isobutyl, i-Bu, -CH2CH(CH3)2), 2-butyl (sec-butyl, sec-Bu, -CH(CH3)CH2CH3), 2-methyl-2-propyl ( tert-Butyl, t-Bu, -C(CH3)3), 1-Pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-Pentyl (-CH(CH3)CH2CH2CH3), 3-Pentyl (-CH(CH2CH3)2), 3-Methyl-1-butyl (iso-pentyl, -CH2CH2CH(CH3)2), 2-Methyl-2-butyl (-C(CH3)2CH2CH3), 3-Methyl-2-butyl (-CH(CH3)CH(CH3)2), 2,2-Dimethyl-1-propyl (neo-pentyl, -CH2C(CH3)3), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (n-hexyl, -CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 5-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 6-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 7-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 8-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 9-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 10-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 11-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 12-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 13-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 14-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 15-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 16-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 17-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 18-methyl-2-pentyl (-C(CH3 H(CH3)CH2CH(CH3)2), 3-Methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-Methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-Dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-Dimethyl-2-butyl (-CH(CH3)C(CH3)3), 2,3-Dimethyl-1-butyl (-CH2CH(CH3)CH(CH3)CH3), 2,2-Dimethyl-1-butyl (-CH2C(CH3)2CH2CH3), 3,3-Dimethyl-1-butyl (-CH2CH2C(CH3)3), 2-methyl-1-pentyl (-CH2CH(CH3)CH2CH2CH3), 3-methyl-1-pentyl (-CH2CH2CH(CH3)CH2CH3), 1-heptyl (n-heptyl), 2-methyl-1-hexyl, 3-methyl-1-hexyl, 2,2-dimethyl-1-pentyl, 2,3-dimethyl-1-pentyl, 2,4-dimethyl-1-pentyl, 3,3-dimethyl-1-pentyl, 2,2,3-trimethyl-1-butyl, 3-ethyl-1-pentyl, 1-octyl (n-octyl), 1-nonyl (n-nonyl), 1-decyl (n-decyl), etc.

[0076] The terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc., without any further definition, mean saturated hydrocarbon groups having the corresponding number of carbon atoms and include all isomeric forms. The alkyl may be a further (combined) group, e.g. C x-y Alkylamino or C x-y When part of alkyloxy, the above definition for alkyl also applies. The term alkylene can also be derived from alkyl. Unlike alkyl, alkylene is bivalent and requires two binding partners. Formally, the second valency is generated by removing a hydrogen atom in alkyl. Corresponding groups are, for example, -CH3 and -CH2-, -CH2CH3 and -CH2CH2- or >CHCH3. "C 1-4The term "alkylene" includes, for example, -(CH2)-, -(CH2-CH2)-, -(CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(CH(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH(CH3)-CH 2-CH2)-, -(CH2-CH(CH3)-CH2)-, -(CH2-C(CH3)2)-, -(C(CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2-C Includes H(CH2CH3))-, -(CH(CH2CH3)-CH2)-, -(CH(CH2CH2CH3))-, -(CH(CH(CH3))2)- and -C(CH3)(CH2CH3)-.

[0077] Other examples of alkylene are methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, hexylene, and the like. Without any further definition, the generic terms propylene, butylene, pentylene, hexylene etc. refer to all the possible isomeric forms with the corresponding number of carbon atoms, i.e. propylene includes 1-methylethylene, butylene includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene. The alkylene may be combined with other groups, such as HO-C x-y Alkyleneamino or H2N-C x-y When part of alkyleneoxy, the above definition for alkylene also applies.

[0078] Unlike alkyl, alkenyl consists of at least two carbon atoms, where at least two adjacent carbon atoms are linked together by a CC double bond, and a carbon atom may be part of only one CC double bond. In the case of an alkyl as defined above having at least two carbon atoms, two hydrogen atoms on adjacent carbon atoms are formally removed and the free valences are saturated to form a second bond, forming the corresponding alkenyl. Examples of alkenyl are vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, 1-methyl-prop-1-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl. , 3-methyl-but-1-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3-methylbutyl, 2,3-dimethyl-but-1-enyl, hexa-1,3-dienyl, hexa-1,4-dienyl, penta-1,4-dienyl, penta-1,3-dienyl, buta-1,3-dienyl, 2,3-dimethylbuta-1,3-dienyl, and the like.

[0079] Furthermore, the general terms propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl etc., without any definition, refer to all the possible isomeric forms with the corresponding number of carbon atoms, i.e. propenyl includes prop-1-enyl and prop-2-enyl, butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl etc. Alkenyls may be in the cis or trans, or E or Z orientation about the double bond. Alkenyl may be substituted with other (combined) groups, e.g. C x-y Alkenylamino or C x-y When part of alkenyloxy, the above definition of alkenyl also applies. Unlike alkylene, alkenylene consists of at least two carbon atoms, where at least two adjacent carbon atoms are linked together by a CC double bond, and a carbon atom can be part of only one CC double bond. In the case of an alkylene as defined above having at least two carbon atoms, two hydrogen atoms at adjacent carbon atoms are formally removed and the free valences are saturated to form a second bond, forming the corresponding alkenylene.

[0080] Examples of alkenylene are ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, hexenylene, and the like. Furthermore, without any definition, the general terms propenylene, butenylene, pentenylene, hexenylene etc. refer to all the possible isomeric forms with the corresponding number of carbon atoms, i.e. propenylene includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 2-methylpropenylene, 1,1-dimethylethenylene and 1,2-dimethylethenylene. Alkenylene may be in the cis or trans, or E or Z orientation about the double bond.

[0081] Alkenylene is, for example, HO-C x-y Alkenyleneamino or H2N-C x-y When it is part of another (combining) group, such as in alkenyleneoxy, the above definition for alkenylene also applies. Unlike alkyl, alkynyl consists of at least two carbon atoms, at least two adjacent carbon atoms are connected together by a CC triple bond. In the case of alkyl as defined above having at least two carbon atoms, in each case two hydrogen atoms at adjacent carbon atoms are formally removed and the free valences are saturated to form two additional bonds to form the corresponding alkynyl. Examples of alkynyl are ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, and the like. Furthermore, without any definition, the generic names propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl etc. refer to all possible isomeric forms with the corresponding number of carbon atoms, i.e. propynyl includes prop-1-ynyl and prop-2-ynyl, butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl, 1-methyl-prop-2-ynyl etc. A hydrocarbon chain, by definition, belongs to an alkynyl moiety if it possesses both at least one double bond and also at least one triple bond.

[0082] Alkynyl is, for example, C x-y Alkynylamino or C x-y When it is part of another (combined) group, such as in alkynyloxy, the above definition for alkynyl also applies. Unlike alkylene, alkynylene consists of at least two carbon atoms, where at least two adjacent carbon atoms are linked together by a CC triple bond. In the case of alkylene as defined above having at least two carbon atoms, in each case two hydrogen atoms at adjacent carbon atoms are formally removed and the free valences are saturated to form two further bonds, forming the corresponding alkynylene. Examples of alkynylene are ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene, and the like.

[0083] Without any further definition, the generic names propynylene, butynylene, pentynylene, hexynylene etc. mean all the possible isomeric forms with the corresponding number of carbon atoms, i.e. propynylene includes 1-methylethynylene, butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene. The alkynylene may be, for example, HO-C x-y Alkynyleneamino or H2N-C x-y When it is part of another (combined) group, such as in alkynyleneoxy, the above definition for alkynylene also applies. Heteroatoms means oxygen, nitrogen and sulfur atoms. Haloalkyl (haloalkenyl, haloalkynyl) is derived from alkyl (alkenyl, alkynyl) as previously defined by replacing one or more hydrogen atoms of the hydrocarbon chain, independently of one another, with halogen atoms which may be identical or different. If haloalkyl (haloalkenyl, haloalkynyl) is further substituted, the substitutions may take place independently of one another in the form of mono- or polysubstitutions in each case on all hydrogen-bearing carbon atoms.

[0084] Examples of haloalkyl (haloalkenyl, haloalkynyl) include -CF3, -CHF2, -CH2F, -CF2CF3, -CHFCF3, -CH2CF3, -CF2CH3, -CHFCH3, -CF2CF2CF3, -CF2CH2CH3, -CF=CF2, -CCl=CH2, -CBr=CH2, -C≡C-CF3, -CHFCH2CH3, -CHFCH2CF3, and the like. The term haloalkylene (haloalkenylene, haloalkynylene) is also derived from haloalkyl (haloalkenyl, haloalkynyl) as previously defined. Unlike haloalkyl (haloalkenyl, haloalkynyl), haloalkylene (haloalkenylene, haloalkynylene) is divalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from the haloalkyl (haloalkenyl, haloalkynyl). Corresponding groups are, for example, -CH2F and -CHF-, -CHFCH2F and -CHFCHF- or >CFCH2F.

[0085] If the corresponding halogen-containing group is part of another (combined) group, the above definition also applies. Halogen relates to fluorine, chlorine, bromine and / or iodine atoms. Cycloalkyl is composed of the subgroups monocyclic, bicyclic and spiro-hydrocarbon rings. The systems are saturated. In bicyclic hydrocarbon rings, two rings are linked together with at least two carbon atoms in common. In spiro-hydrocarbon rings, one carbon atom (spiro atom) belongs to both rings together. If cycloalkyl is substituted, the substitutions may take place independently of one another in the form of mono- or polysubstitutions in each case on all hydrogen-carrying carbon atoms. Cycloalkyl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthyl), bicyclo[2.2.1]heptyl (norbornyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo[3.1.1]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl, and the like. Cycloalkyl may be, for example, C x-y Cycloalkylamino, C x-y Cycloalkyloxy or C x-y When it is part of another (combined) group, such as in cycloalkylalkyl, the above definition for cycloalkyl also applies. If the free valence of a cycloalkyl is saturated, an alicyclic group is obtained.

[0086] The term cycloalkylene can therefore be derived from cycloalkyl as previously defined. Cycloalkylene, unlike cycloalkyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a cycloalkyl. Corresponding groups include, for example: Cyclohexyl and [ka] (cyclohexylene). The cycloalkylene is, for example, HO-C x-y Cycloalkyleneamino or H2N-C x-y When it is part of another (combined) group, such as in cycloalkyleneoxy, the above definition for cycloalkylene also applies. Cycloalkenyls are also composed of the subgroups monocyclic, bicyclic and spirohydrocarbon rings. However, the systems are unsaturated, i.e., there is at least one C-C double bond, but they are not aromatic. In the case of cycloalkyls as defined above, two hydrogen atoms are formally removed at adjacent ring carbon atoms, saturating the free valences and forming a second bond to obtain the corresponding cycloalkenyl.

[0087] If a cycloalkenyl is substituted, the substitutions may take place independently of one another in the form of mono- or polysubstitutions in each case on all hydrogen-carrying carbon atoms. The cycloalkenyl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system. Examples of cycloalkenyl are cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2-enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobuta-1,3-dienyl, cyclopenta -1,4-dienyl, cyclopenta-1,3-dienyl, cyclopenta-2,4-dienyl, cyclohexa-1,3-dienyl, cyclohexa-1,5-dienyl, cyclohexa-2,4-dienyl, cyclohexa-1,4-dienyl, cyclohexa-2,5-dienyl, bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl), bicyclo[2.2.1]hept-2-enyl (norbornenyl), spiro[4,5]dec-2-enyl, and the like.

[0088] Cycloalkenyl is, for example, C x-y Cycloalkenylamino, C x-y Cycloalkenyloxy or C x-y When it is part of another (combined) group, such as in cycloalkenylalkyl, the above definition for cycloalkenyl also applies. If the free valence of a cycloalkenyl is saturated, an unsaturated alicyclic group is obtained.

[0089] The term cycloalkenylene can therefore be derived from cycloalkenyl as previously defined. Cycloalkenylene, unlike cycloalkenyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from cycloalkenyl. Corresponding groups include, for example: Cyclopentenyl and [ka] (cyclopentenylene), etc. Cycloalkenylene is, for example, HO-C x-y Cycloalkenyleneamino or H2N-C x-y When it is part of another (combined) group, such as in cycloalkenyleneoxy, the above definition for cycloalkenylene also applies.

[0090] Aryl represents a monocyclic, bicyclic or tricyclic carbocycle having at least one aromatic carbocycle. Preferably, it represents a monocyclic group having 6 carbon atoms (phenyl) or a bicyclic group having 9 or 10 carbon atoms (two 6-membered rings or one 6-membered and one 5-membered ring), the second ring of which may be aromatic but also partially saturated. If an aryl is substituted, the substitutions may take place independently of one another in the form of mono- or polysubstitutions in each case on all hydrogen-carrying carbon atoms. The aryl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system. Examples of aryl are phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2-dihydronaphthyl), fluorenyl, etc. Phenyl is most preferred. In case aryl is part of other (combined) groups, such as in, for example, arylamino, aryloxy or arylalkyl, the above definition of aryl also applies. If the free valence of an aryl is saturated, an aromatic group is obtained.

[0091] The term arylene can also be derived from aryl as previously defined. Unlike aryl, arylene is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from an aryl. The corresponding group is, for example: Phenyl and [ka] (o, m, p-phenylene), naphthyl and [ka] And so on.

[0092] If arylene is part of other (combined) groups, such as in, for example, HO-aryleneamino or H2N-aryleneoxy, the above definition for arylene also applies. Heterocyclyl represents a ring system derived from cycloalkyl, cycloalkenyl and aryl as previously defined by replacing one or more -CH2- groups in the hydrocarbon ring, independently of one another, with -O-, -S- or -NH- groups, or by replacing one or more =CH- groups with =N- groups, where a total of up to 5 heteroatoms may be present, at least one carbon atom must be present between two oxygen atoms and between two sulfur atoms or between an oxygen and a sulfur atom, and the ring as a whole must have chemical stability. Heteroatoms may be present in all possible oxidation stages (sulfur → sulfoxide-SO-, sulfone-SO2-, nitrogen → N-oxide). In heterocyclyl, there is no heteroaromatic ring, i.e. the heteroatoms are not part of the aromatic system.

[0093] A direct corollary of cycloalkyl, cycloalkenyl, and aryl is that heterocyclyl is comprised of monocyclic heterocycles, bicyclic heterocycles, tricyclic heterocycles, and spiro-heterocycles, which are moieties that can exist in saturated or unsaturated form. Unsaturated means that there is at least one double bond in the ring system, but no heteroaromatic system is formed. In a bicyclic heterocycle, two rings are linked together to have at least two (hetero)atoms in common. In a spiro-heterocycle, one carbon atom (spiro atom) belongs to both rings together. If a heterocyclyl is substituted, the substitutions may occur independently of one another in the form of mono- or polysubstitutions in each case on all hydrogen-carrying carbon and / or nitrogen atoms. The heterocyclyl itself may be linked to the molecule as a substituent via any suitable position of the ring system. Substituents on a heterocyclyl are not included in the number of members of the heterocyclyl.

[0094] Examples of heterocyclyls are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-di. Oxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [1,4]-oxazepanyl, tetrahydrothienyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydro-pyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide, tetrahydrothienyl-S,S-dioxide, homothiomorpholinyl-S-oxide cido, 2,3-dihydroazeto, 2H-pyrrolyl, 4H-pyranyl, 1,4-dihydropyridinyl, 8-aza-bicyclo[3.2.1]octyl, 8-aza-bicyclo[5.1.0]octyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo[2.2.1]heptyl, 1-aza-bicyclo[2.2.2]octyl, 3,8-diaza- Bicyclo[3.2.1]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl, 2,6-diaza-bicyclo[3.2.2]nonyl, 1,4-dioxa-spiro[4.5]decyl, 1-oxa-3,8-diaza-spiro[4.5]decyl, 2,6-diaza-spiro[3.3]heptyl, 2,7-diaza-spiro[4.4]nonyl, 2,6-diaza-spiro[3.4]octyl, 3,9-diaza-spiro[5.5]undecyl, 2.8-diaza-spiro[4,5]decyl, etc.

[0095] Further examples are the structures illustrated below, which may be attached via each hydrogen-bearing atom (exchanged for hydrogen). [ka] [ka] [ka]

[0096] Preferably, the heterocyclyl is a 4- to 8-membered monocyclic ring having 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur. Preferred heterocyclyls are piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, azetidinyl, tetrahydropyranyl, tetrahydrofuranyl. In case heterocyclyl is part of other (combined) groups, such as, for example, in heterocyclylamino, heterocyclyloxy or heterocyclylalkyl, the above definition of heterocyclyl also applies. If the free valence of a heterocyclyl is saturated, a heterocyclic group is obtained. The term heterocyclylene is also derived from heterocyclyl as previously defined. Heterocyclylene, unlike heterocyclyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heterocyclyl. Corresponding groups include, for example: Piperidinyl and

[0097] [ka] 2,3-Dihydro-1H-pyrrolyl and [ka] And so on. If heterocyclylene is part of other (combined) groups, such as, for example, in HO-heterocyclyleneamino or H2N-heterocyclyleneoxy, the above definition of heterocyclylene also applies.

[0098] Heteroaryl represents a monocyclic heteroaromatic ring or a polycyclic ring with at least one heteroaromatic ring, which, compared to the corresponding aryl or cycloalkyl(alkenyl), contains one or more identical or different heteroatoms selected from nitrogen, sulfur and oxygen, instead of one or more carbon atoms, and the resulting group must be chemically stable.The prerequisite for the presence of heteroaryl is the heteroatom and the heteroaromatic system. When heteroaryl is substituted, the substitutions can occur independently of each other in the form of monosubstitution or polysubstitution on all hydrogen-bearing carbon and / or nitrogen atoms in each case.Heteroaryl itself can be linked to the molecule as a substituent via any suitable position of the ring system, both carbon and nitrogen.Substituents on heteroaryl are not included in the number of members of heteroaryl.

[0099] Examples of heteroaryl are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyridyl-N-oxide, pyrrolyl-N-oxide, pyrimidinyl-N-oxide, pyridazinyl-N-oxide, pyrazinyl-N-oxide, imidazolyl-N-oxide, isoxazolyl-N-oxide, oxazolyl-N-oxide, thiazolyl-N-oxide, oxadiazolyl-N-oxide, thiadiazolyl-N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, indolyl, isoindolyl, benzofuryl, benzothienyl, benzoxazolyl, benzo, zothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzotriazinyl, indolizinyl, oxazolopyridyl, imidazopyridyl, naphthyridinyl, benzoxazolyl, pyridopyridyl, pyrimidopyridyl, purinyl, pteridinyl, ben These include zothiazolyl, imidazopyridyl, imidazothiazolyl, quinolinyl-N-oxide, indolyl-N-oxide, isoquinolyl-N-oxide, quinazolinyl-N-oxide, quinoxalinyl-N-oxide, phthalazinyl-N-oxide, indolizinyl-N-oxide, indazolyl-N-oxide, benzothiazolyl-N-oxide, and benzimidazolyl-N-oxide.

[0100] Further examples are the structures illustrated below, which may be attached via each hydrogen-bearing atom (exchanged for hydrogen). [ka]

[0101] Preferably, the heteroaryl is a 5- to 6-membered monocyclic or a 9- to 10-membered bicyclic ring, each having 1 to 4 heteroatoms independently selected from oxygen, nitrogen and sulfur. In case heteroaryl is part of other (combined) groups, such as, for example, in heteroarylamino, heteroaryloxy or heteroarylalkyl, the above definition of heteroaryl also applies.

[0102] If the free valence of a heteroaryl is saturated, a heteroaromatic group is obtained. The term heteroarylene is also derived from heteroaryl, as previously defined. Heteroarylene, unlike heteroaryl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heteroaryl. Corresponding groups include, for example: Pyrrolyl and [ka] And so on.

[0103] If heteroarylene is part of other (combined) groups, such as in, for example, HO-heteroaryleneamino or H2N-heteroaryleneoxy, the above definition of heteroarylene also applies. Substituted means that a hydrogen atom directly attached to the atom in question is replaced by another atom or an atom of another group (substituent). Depending on the starting conditions (number of hydrogen atoms), mono- or polysubstitutions can occur on an atom. Substitution with a specific substituent is only conceivable if the allowed valencies of the substituent and the atom to be substituted correspond to each other and the substitution results in a stable compound (i.e., a compound that is not spontaneously transformed, for example, by rearrangement, cyclization or elimination).

[0104] Divalent substituents such as =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N2 can only be substituents on carbon atoms, while divalent substituents =O and =NR can also be substituents on sulfur. Generally, substitution can only be carried out with divalent substituents on ring systems, requiring the replacement of two geminal hydrogen atoms, i.e. hydrogen atoms attached to the same carbon atom that is saturated before substitution. Substitution with divalent substituents is therefore only conceivable on -CH2- groups or sulfur atoms of the ring system (only =O or =NR groups, one or two =O groups are possible, or, for example, one =O group and one =NR group, each group replacing a free electron pair). Stereochemistry / Solvates / Hydrates. Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name is intended to encompass tautomers and all stereo, optical and geometric isomers (e.g., enantiomers, diastereoisomers, E / Z isomers), as well as racemates thereof, as well as mixtures of different ratios of the individual enantiomers, mixtures of diastereoisomers, or mixtures of any of the foregoing forms, where such isomers and enantiomers exist, as well as pharma- ceutically acceptable salts thereof, as well as salts, including solvates thereof, e.g., solvates and hydrates of the free compounds or hydrates, including solvates and hydrates of a salt of the compound. In general, substantially pure stereoisomers can be obtained according to synthetic principles known to those skilled in the art, for example, by separation of the corresponding mixtures, by using stereochemically pure starting materials, and / or by stereoselective synthesis. It is well known in the art how to prepare optically active forms, for example, by resolution or synthesis of racemic forms, starting from, for example, optically active starting materials and / or by using chiral reagents.

[0105] Enantiomerically pure compounds or intermediates of the present invention may be prepared via asymmetric synthesis, for example by the preparation and subsequent separation of suitable diastereomeric compounds or intermediates which can be separated by known methods (e.g. by chromatographic separation or crystallization), and / or by the use of chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries. Furthermore, it is known to those skilled in the art how to prepare enantiomerically pure compounds from the corresponding racemic mixtures, for example by chromatographic separation of the corresponding racemic mixtures on chiral stationary phases, or by resolution of the racemic mixtures using suitable resolving agents, for example by formation of diastereoisomeric salts of the racemates with optically active acids or bases, subsequent resolution of the salts and release of the desired compounds from the salts, or by derivatization of the corresponding racemates with optically active chiral auxiliary reagents, subsequent diastereoisomeric separation and removal of the chiral auxiliary, or by kinetic resolution of the racemates (for example by enzymatic resolution), by enantioselective crystallization from a consortium of bipolar crystals under suitable conditions, or by (fractional) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.

[0106] Salts. The phrase "pharmaceutical acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and which are commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. As used herein, "pharmaceutical acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound has been modified by making acid or base salts thereof. Examples of pharmaceutical acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues, such as amines, alkali or organic salts of acidic residues, such as carboxylic acids. For example, such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid and tartaric acid.

[0107] Further pharma- ceutically acceptable salts can be formed with cations from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane. The pharma- ceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of an appropriate base or acid in water or an organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. Other acid salts than those mentioned above, useful for example for purifying or isolating the compounds of the invention (eg trifluoroacetates), also form part of the invention.

[0108] for example [ka] In the representation, the letter A has the function of designating a ring for clarity, for example to indicate the attachment of the ring to another ring.

[0109] for example, [ka] In the representation, the dashed line indicates when ring A (for each definition of A) is fused to an adjacent ring, i.e., when two adjacent atoms of ring A are common to such adjacent ring.

[0110] For bivalent groups where it is important to determine which adjacent groups are attached to which valencies and which have them, the corresponding bond partners are indicated by square brackets where necessary for clarity purposes, as in the following representation: [ka] or (R 2 )-C(O)NH- or (R 2 )-NHC(O)-. A group or substituent may be replaced with a corresponding group designation, e.g., R a , R b ) are often selected from among several alternative groups / substituents having the same meaning. When such groups are used repeatedly to define the compounds according to the invention in different parts of the molecule, it is pointed out that the various uses are completely independent of each other. A therapeutically effective amount for purposes of this invention means an amount of a substance that is capable of obviating the symptoms of the disease or preventing or alleviating these symptoms or prolonging the survival of the treated patient.

[0111] List of abbreviations [Table 2] TIFF0007590996000058.tif223148 TIFF0007590996000059.tif52130

[0112]

[0023] Features and advantages of the present invention will become apparent from the following detailed examples which illustrate, by way of example, the principles of the invention without limiting its scope. Preparation of compounds according to the invention General Unless otherwise stated, all reactions are carried out on commercially available equipment using methods customarily used in chemical laboratories. Starting materials that are sensitive to air and / or moisture are stored under protective gas and the corresponding reactions and manipulations are carried out under protective gas (nitrogen or argon). The compounds according to the invention are named according to the CAS rules using the software Autonom (Beilstein). If a compound is to be represented by both a structural formula and its nomenclature, in case of a conflict, the structural formula takes precedence. Microwave reactions are carried out in a Biotage generator / reactor or a CEM Explorer or an Anton Paar Synthos 3000 or Monowave 3000 in a closed vessel (preferably 2, 5 or 20 mL), preferably with stirring.

[0113] Chromatography Thin layer chromatography is performed on Merck preformed silica gel 60 TLC plates on glass (with fluorescent indicator F-254). Preparative high pressure chromatography (HPLC) of exemplary compounds according to the invention is carried out using Waters columns (designation: Sunfire C18 OBD, 10 μm, 30×100 mm, part number 186003971, X-Bridge C18 OBD, 10 μm, 30×100 mm, part number 186003930). Compounds are eluted using different gradients of H2O / AcCN, and 0.2% HCOOH is added to the water (acidic conditions). For chromatography under basic conditions, water is made basic according to the following recipe: 5 mL of ammonium bicarbonate solution (158 g in 1 L H2O) and 2 mL 32% ammonia (aq) with H2O up to 1 L. Supercritical fluid chromatography (SFC) of intermediates and example compounds according to the invention is carried out on a JASCO SFC-system using the following columns: Chiralcel OJ (250×20 mm, 5 μm), Chiralpak AD (250×20 mm, 5 μm), Chiralpak AS (250×20 mm, 5 μm), Chiralpak IC (250×20 mm, 5 μm), Chiralpak IA (250×20 mm, 5 μm), Chiralcel OJ (250×20 mm, 5 μm), Chiralcel OD (250×20 mm, 5 μm), Phenomenex Lux C2 (250×20 mm, 5 μm). Analytical HPLC (reaction monitoring) of intermediate compounds is carried out using columns from Waters and Phenomenex. The analytical equipment is also equipped with a mass detector in each case.

[0114] HPLC-Mass Spectroscopy / UV-Spectroscopy Retention Time / MS-ESI for Characterizing Exemplary Compounds According to the Invention + is generated using an Agilent HPLC-MS instrument (High Performance Liquid Chromatography with Mass Detector). Compounds eluting in the injection peak have retention times t Ret .=0.00. HPLC-Method (Preparative) NP1 NP purification: GLASS COLUMN Column: 100-200 mesh size silica gel Solvent: A: DCM, B: MeOH Detection: KMnO4 Flow rate: 100mL / min Gradient: 0-60 min: 1% B 60-100 minutes: Varies 100~200 minutes: 10%B Prep.HPLC1 HPLC: 333 and 334 pumps Column: Waters X-Bridge C18 OBD, 10 μm, 30 x 100 mm, part number 186003930 Solvents: A: 10 mM NH4HCO3 in H2O, B: AcCN (HPLC grade) Detection: UV / Vis-155 Flow rate: 50mL / min Gradient: 0.00-1.50 min: 1.5% B 1.50~7.50 min: Varies 7.50~9.00 minutes: 100%B

[0115] Prep.HPLC2 HPLC: 333 and 334 pumps Column: Waters Sunfire C18 OBD, 10 μm, 30 x 100 mm, part number 186003971 Solvents: A: HO + 0.2% HCOOH, B: AcCN (HPLC grade) + 0.2% HCOOH Detection: UV / Vis-155 Flow rate: 50mL / min Gradient: 0.00-1.50 min: 1.5% B 1.50~7.50 min: Varies 7.50~9.00 minutes: 100%B

[0116] HPLC-Method (Analysis) LCMSBAS HPLC: Agilent 1100 Series MS: Agilent LC / MSD SL Column: Phenomenex Mercury Gemini C18, 3μm, 2x20mm, part number 00M-4439-B0-CE Solvents: A: 5mM NH4HCO3 / 20mM NH3 in H2O, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 120-900m / z Flow rate: 1.00mL / min Column temperature: 40℃ Gradient: 0.00-2.50 min: 5% → 95%B 2.50~2.80 minutes: 95%B 2.81~3.10 minutes: 95%→5%B

[0117] LCMSBAS1 HPLC: Agilent 1200 Series MS: Agilent 6140 Column: Waters X-Bridge C18 column, 2.5 μm particle size, 2.1 × 20 m Solvents: A: 20mM NH4HCO3 / NH3 in H2O, B: AcCN (HPLC grade) Detection: MS: positive and negative modes UV: 170nM in the range of 230-400nM Mass range: 120-900m / z Flow rate: 1.00mL / min Column temperature: 60℃ Gradient: 0.00-1.50 min: 10% → 95%B 1.50~2.00 minutes: 95%B 2.00~2.10 minutes: 95%→10%B

[0118] LCMS3, basisch_1 HPLC: Gilent 1100 series MS: Agilent LC / MSD (API-ES+ / -3000V, Quadrupol, G6140) Column: Waters, X-Bridge C18, 2.5 μm, 2.1 x 20 mm column Solvents: A: 20 mM NH4HCO3 / NH3 in H2O pH 9, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 120-900m / z Flow rate: 1.00mL / min Column temperature: 60℃ Gradient: 0.00-1.50 min: 10% → 95%B 1.50~2.00 minutes: 95%B 2.00~2.10 minutes: 95%→10%B

[0119] LCMS_TCG HPLC: Shimadzu LC20 MS:API 2000 Column: Zorbax Extend C18 (50 x 4.6 mm, 5u, 80A) Solvents: A: 10 mM NH4OAc in HO, B: AcCN (HPLC grade) Detection: MS: Positive mode Mass range: 100-800m / z Flow rate: 1.00mL / min Column temperature: 25℃ Gradient: 0.00-1.50 min: 20% → 98%B 1.50~6.00 minutes: 98%B 6.00~7.00 minutes: 98%→20%B

[0120] VAB HPLC: Agilent 1100 / 1200 series MS: Agilent LC / MSD SL Column: Waters X-Bridge BEH C18, 2.5 μm, 2.1 × 30 mm XP Solvents: A: 5mM NH4HCO3 / 19mM NH3 in H2O, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 100-1200m / z Flow rate: 1.40mL / min Column temperature: 45℃ Gradient: 0.00-1.00 min: 5% B → 100% B 1.00~1.37 minutes: 100%B 1.37~1.40 minutes: 100%→5%B

[0121] VAS HPLC: Agilent 1100 / 1200 series MS: Agilent LC / MSD SL Column: YMC TriART C18 2.0 x 30 mm, 3 μm Solvents: A: HO + 0.2% formic acid, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 105-1200 m / z Flow rate: 1.40mL / min Column temperature: 35℃ Gradient: 0.0 min: 5% B 0.0~1.00 minutes: 5%B→100%B 1.00~1.37 minutes: 100%B 1.37~1.40 minutes: 100%B→5%B

[0122] 4_BAS_PN HPLC: Agilent 1100 Series MS: Agilent LC / MSD SL Column: Waters, X-Bridge C18, 3.5 μm, 2.1 x 30 mm column Solvents: A: 20 mM NH4HCO3 / NH3 in H2O pH 9, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 150-900m / z Flow rate: 1.40mL / min Column temperature: 45℃ Gradient: 0.00-1.00 min: 15% → 95%B 1.00~1.37 minutes: 95%B 1.37~1.40 minutes: 95%→15%B

[0123] 2_FEC_PN HPLC: Agilent 1100 Series MS: Agilent LC / MSD SL Column: YMC Triart C18 2.0 x 30 mm, 3.0 μm Solvents: A: HO+0.1% HCOOH, B: AcCN (HPLC grade) Detection: MS: positive and negative modes Mass range: 150-900m / z Flow rate: 1.40mL / min Column temperature: 45℃ Gradient: 0.00-1.00 min: 15% → 95%B 1.00~1.37 minutes: 95%B 1.37~1.40 minutes: 95%→15%B

[0124] The compounds and intermediates according to the present invention are prepared by the synthetic methods described below, where the substituents of the general formula have the meanings indicated above.These methods are intended as illustrations of the present invention, without restricting the subject matter and scope of the compounds claimed to these examples.If the preparation of starting compounds is not described, the starting compounds are commercially available, or the synthesis is described in the prior art, or they can be prepared in analogy to known prior art compounds or the methods described herein, i.e., it is within the skill of an organic chemist to synthesize such compounds.Substances described in the literature can be prepared according to published synthetic methods.

[0125] General reaction schemes and synthetic routes summarized Compounds (I) according to the invention can be synthesized using amide formation of macrocyclization starting from open-chain aminobenzimidazole C-1 (Scheme 1, Method A or A'). Macrocyclization can be achieved directly using a strong base such as, for example, 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (Scheme 1, Method A), or the ester functionality of C-1 is first cleaved and then the amide bond is formed using a coupling reagent such as TBTU or HATU (Scheme 1, Method A').

[0126] Alternatively, compounds (I) according to the invention can be synthesized starting from the open-chain aminobenzimidazole C-2 and applying the macrocyclization ether formation (Scheme 1, Method B). Different methods can be used for the ether formation, such as the MITSUNOBU reaction or a two-step method in which the alcohol is first activated by conversion to a halogen or sulfone ester and ring closure by nucleophilic substitution. Scheme 1

[0127] [ka]

[0128] The key ether intermediate C-1 for macrocyclization can be synthesized applying three different strategies (Scheme 2): One possibility is ether formation using intermediates A-2 and B-1 (Scheme 2, Method D). A second option is an alkylation reaction using aminobenzimidazole A-1 and ether intermediate B-2 obtained by reaction of intermediates E-1 and B-1 (→ Scheme 2, Method E). The key step of the third ring-closing strategy is the aminobenzimidazole formation reaction applying a reagent such as cyanogen bromide (see, for example, WO2005 / 079791, WO2005 / 070420, WO2004 / 014905). To do this, the nitro group of the ether intermediate C-3 needs to be reduced, which can be achieved, for example, using hydrogen gas and a catalyst such as Pd / C or Ra-Ni. Intermediate C-3 is synthesized by an ether formation reaction starting from A-3 and B-1 (→ Scheme 2, Method F). Scheme 2

[0129] [ka]

[0130] The key amide intermediate C-2 can be synthesized by amide formation starting from intermediate A-4 or A-5 reacted with B-3 or B-4 using coupling reagents such as HATU or TBTU (→ Scheme 3). Scheme 3

[0131] [ka]

[0132] Aminobenzimidazole A-2 can be synthesized by applying an alkylation reaction starting from aminobenzimidazole A-1 and alkylating agent E-1 (→ Scheme 4). In addition, aminobenzimidazole A-2 can also be obtained from A-4 via a deprotection reaction followed by conversion of the hydroxy group to a halogen or sulfone ester. Aminobenzimidazole A-4 can be synthesized by applying a nucleophilic aromatic substitution reaction of A-6 and E-2 (e.g. Helvetica Chimica Acta 2013, 96, 2160-2172, Organic Preparations and Procedures Int. 2004, 36, 76-81), followed by reduction of the nitro group of A-7 and aminobenzimidazole formation reaction by using a reagent such as cyanogen bromide (e.g. WO2005 / 079791, WO2005 / 070420, WO2004 / 014905). Intermediate A-3 can be synthesized from A-7 via a deprotection reaction followed by conversion of the free hydroxy group to a halogen or sulfone ester. Intermediate A-5 can be synthesized from A-7 by reduction of the nitro group of A-7 followed by reaction with 1-(1H-imidazole-1-carboximidoyl)-1H-imidazole. Scheme 4

[0133] [ka]

[0134] Intermediate B-1 can be synthesized either starting from 2-halogen-isonicotinic acid derivative F-1 and boronic acid derivative B-5 by applying the SUZUKI reaction (see, for example, J. Org. Chem., 2007, 72, 4067-4072; Org. Lett., 2011, 13, 252-255; J. Org. Chem., 2004, 69, 7779-7782) followed by deprotection of the hydroxy group of B-6, or starting from boronic acid derivative F-2 and electrophile B-7, also applying the SUZUKI reaction, followed by deprotection of the heteroaromatic ring system of B-8 (→ Scheme 5). Intermediates B-4 and B-3 can be synthesized via ester cleavage of B-6 and B-8, respectively. Scheme 5

[0135] [ka]

[0136] Synthesis of intermediate E-2 Synthesis of E-2a [ka] Experimental procedure for synthesizing IM-2 A stirred solution of starting material IM-1 (10.0 g, 42.87 mmol) in THF (40.0 mL) is cooled to -78 °C. Sodium bis(trimethylsilyl)amide (47.2 mL, 47.16 mmol, 1.1 eq) is added and the reaction mixture is stirred at -78 °C for 1 h. Allyl bromide (15.3 mL, 171.48 mmol, 4.0 eq) is then added and the reaction mixture is stirred at -78 °C for 1 h. The reaction mixture is then allowed to warm slowly to room temperature. The reaction is quenched with a saturated aqueous solution of NH4Cl and extracted with DCM (2x). The combined organic layers are dried over MgSO4, filtered and the solvent is evaporated under reduced pressure to give intermediate IM-2 (HPLC-MS: (M+H) + =274, t Ret. = 1.4 min, method LCMS3, basisch_1).

[0137] Experimental procedure for synthesizing IM-3 To a stirred solution of IM-2 (10.5 g, 38.42 mmol) in THF (40.0 mL) and water (10.0 mL) LiOH (2.8 g, 115.25 mmol, 3.0 eq) and H2O2 (11.9 mL, 115.25 mmol, 3.0 eq) are added. The mixture is acidified to pH 1-2 using 1N aqueous HCl and extracted with DCM (2x). After the combined organic layers are dried over MgSO4, the solution is filtered and the solvent is evaporated under reduced pressure to give the product IM-3. The crude product is used for further synthesis without any additional purification.

[0138] Experimental procedure for synthesizing IM-4 To a stirred solution of IM-3 (4.3 g, 37.67 mmol) in dioxane (15.0 mL) DIPEA (19.3 mL, 113.02 mmol, 3.0 eq) and HATU (17.2 g, 45.21 mmol, 1.2 eq) are added. The reaction mixture is stirred at room temperature for 5 min. Dibenzylamine (7.4 g, 37.67 mmol, 1.0 eq) is then added and stirring at room temperature is continued for 3 h. The crude product is purified by normal phase chromatography (DCM / MeOH 95:5) and reverse phase chromatography (method: prep. HPLC2) to give the desired product IM-4 (HPLC-MS: (M+H) + =294, t Ret. = 1.5 min, method LCMS3, basisch_1).

[0139] Experimental procedure for synthesizing IM-5 IM-4 (4.3 g, 14.66 mmol) is dissolved in THF (5.0 mL), cooled to 0 °C, and a solution of 9-borabicyclo[3.3.1]nonane (73.3 mL, 36.64 mmol, 2.5 eq) in THF is added. The reaction mixture is stirred at room temperature for 1 h. Then, 1 M aqueous NaOH is added. After the reaction mixture is cooled to 0 °C, H2O2 (15.0 mL, 146.56 mmol, 10.0 eq) is added. After the addition, the reaction mixture is stirred at room temperature for 16 h. The reaction mixture is diluted with water and extracted with EtOAc (2x). The combined organic layers are dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (method: prep. HPLC2) to give the desired product IM-5 (HPLC-MS: (M+H) + =312, t Ret. = 1.2 min, method LCMS3, basisch_1).

[0140] Experimental procedure for synthesizing IM-6 IM-5 (30.0 g, 96.33 mmol) is dissolved in THF (300.0 mL) and the solution is cooled to 0 °C. 1M LiAlH4 in THF (674.3 mL, 674.33 mmol, 7.0 eq) is added and the reaction mixture is stirred at room temperature for 2 h. The reaction is then quenched with saturated aqueous Na2SO4 (1 mL), filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (method: Combiflash) to give product IM-6 (HPLC-MS: (M+H) + =298, t Ret. = 1.7 min, method LCMS3, basisch_1).

[0141] Experimental procedure for synthesizing IM-7 To a stirred solution of IM-6 (10.0 g, 33.62 mmol) in DCM (100.0 mL) is added TEA (23.3 mL, 168.10 mmol, 5.0 eq), DMAP (4.1 g, 33.62 mmol, 1.0 eq) and TBDMS-Cl (6.1 g, 40.35 mmol, 1.2 eq). The reaction mixture is stirred at room temperature for 3 h. The reaction mixture is then diluted with water and extracted with DCM. After drying over MgSO4 and filtration, the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (method: Combiflash) to give the desired product IM-7 (HPLC-MS: (M+H) + = 412, t Ret. =4.1 min, method LCMS_TCG).

[0142] Experimental procedure for the synthesis of E-2a To a stirred solution of IM-7 (75.0 g, 182.17 mmol) in MeOH (750.0 mL) is added Pd / C (3.9 g, 18.22 mmol, 10 mol%, 0.1 eq) and the reaction mixture is stirred at room temperature under 3 bar hydrogen pressure for 3 h. The reaction mixture is filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (Method NP1) to give the pure product E-2a. (HPLC-MS: (M+H) + =232)

[0143] Synthesis of E-2b and E-2c [ka] Experimental procedure for synthesizing IM-8 and IM-9 To a stirred solution of IM-4 (50.0 g, 0.170 mol) in water (750.0 mL) and THF (1.250 L) is added N-methyl-morpholine oxide (26.3 mL, 0.256 mol, 1.5 eq). After stirring for 10 min at room temperature, OsO4 (5.4 g, 1.70 mmol, 0.01 eq) is added to the reaction mixture. Stirring at room temperature is continued for 16 h. Brine is then added to the reaction mixture and extraction is performed using EtOAc. The combined organic layers are dried over MgSO4, filtered and concentrated to give the crude product. Purification by normal phase chromatography gives the pure product as a mixture of diastereomers IM-8 and IM-9 (HPLC-MS: (M+H) + =328).

[0144] Experimental procedure for synthesizing IM-10 and IM-11 To a stirred solution of a mixture of diastereomers IM-8 and IM-9 (40.0 g, 0.122 mol) in DMF (400.0 mL) is added 2,2-dimethoxypropane (17.8 g, 0.171 mol, 1.4 eq). After stirring at room temperature for 10 min, CSA (3.3 g, 0.014 mol, 0.1 eq) is added and the reaction mixture is stirred at room temperature for 16 h. Brine is then added to the reaction mixture and extraction is performed using EtOAc. The combined organic layers are washed with saturated aqueous Na2CO3, dried over MgSO4, filtered and the filtrate is concentrated under reduced pressure to give the crude product. The diastereomers are purified and separated by normal phase chromatography to give the pure products IM-10 and IM-11.

[0145] Experimental procedure for synthesizing IM-12 Diastereomer IM-10 (11.5 g, 0.031 mol) is dissolved in THF (150.0 mL) and cooled to 0° C. Then LAH (8.3 g, 0.219 mol, 7.0 eq) is added to the stirred solution and the reaction mixture is stirred at room temperature for 2 h. The reaction is quenched by addition of saturated aqueous Na2SO4 (1 mL), filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give product IM-12. The product IM-13 is accessible in an analogous manner starting from the diastereomer IM-11.

[0146] Experimental procedure for the synthesis of E-2b To a stirred solution of IM-12 (5.7 g, 0.016 mol) in MeOH (60.0 mL) is added Pd / C (0.4 g, 2.0 mmol, 10 mol%, 0.1 eq) and the reaction mixture is stirred at room temperature under 3 bar hydrogen pressure for 3 h. The reaction mixture is then filtered and concentrated under reduced pressure to give the crude product, which is purified by normal phase chromatography to give product E-2b. The product E-2c is accessible in an analogous manner starting from diastereomer IM-13.

[0147] Synthesis of E-2d [ka] Experimental procedure for synthesizing IM-14 A stirred solution of IM-1 (10.0 g, 42.87 mmol) in DCM (25.0 mL) is cooled to -78 °C and 1M Bu2BOTf in DCM (72.9 mL, 72.88 mmol, 1.7 eq) and TEA (14.6 mL, 107.18 mmol, 2.5 eq) is added. The reaction mixture is then stirred at -78 °C for 10 min. Stirring is continued at 0 °C for 1 h. The reaction mixture is cooled again to -78 °C, followed by slow addition of 3-(tert-butyl-dimethyl-silanyloxy)-propionaldehyde (8.1 g, 42.87 mmol, 1.0 eq) and stirring at -78 °C for 20 min. After stirring at 0° C. for another hour, the reaction is quenched by successive addition of phosphate buffer (pH=7, 40 mL), MeOH (112 mL), and 30% H2O2 in MeOH (120 mL). Stirring is continued at 0° C. for 1 hour. Water is then added to the reaction mixture and extraction is performed using DCM. The organic layer is dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (n-hexane / EtOAc) to give the desired product IM-14.

[0148] Experimental procedure for synthesizing IM-15 A stirred solution of IM-14 (8.0 g, 18.98 mmol) in DCM (80.0 mL) is cooled to 0° C. and 2,6-lutidine (5.5 mL, 47.45 mmol, 2.5 eq) and TBDMSOTf (5.7 mL, 24.67 mmol, 1.3 eq) are added. The reaction mixture is stirred at room temperature for 3 h. The reaction mixture is then diluted with water and extracted with DCM. The organic layer is dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give the desired product IM-15.

[0149] Experimental procedure for synthesizing IM-16 A stirred solution of IM-15 (4.0 g, 7.47 mmol) in THF (15.0 mL) and HO (2.0 mL) is cooled to 0° C. and NaBH (1.4 g, 37.32 mmol, 5.0 eq) is added. The reaction mixture is stirred at room temperature for 16 h. The solvent is then evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give the desired product IM-16.

[0150] Experimental procedure for synthesizing IM-17 A stirred solution of IM-16 (2.8 g, 7.72 mmol) in THF (80.0 mL) is cooled to 0 °C and PPh3 (5.1 g, 19.30 mmol, 2.5 eq) and DEAD (3.1 mL, 19.30 mmol, 2.5 eq) are added. The reaction mixture is stirred at 0 °C for 10 min. Isoindole-1,3-dione (1.7 g, 11.58 mmol, 1.5 eq) is then added and the reaction mixture is stirred at room temperature for 16 h. The reaction is then quenched by the addition of saturated aqueous NaHCO3 and extraction is performed using EtOAc. The organic layer is dried over Na2SO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give the desired product IM-17.

[0151] Experimental procedure for synthesizing E-2d To a stirred solution of IM-17 (4.0 g, 8.13 mmol) in EtOH (40.0 mL), hydrazine hydrate (4.0 mL, 81.33 mmol, 10.0 eq) is added and the reaction mixture is stirred at reflux for 2 h. A white precipitate forms. The reaction mixture is cooled to room temperature and filtered. The filtrate is concentrated to dryness under reduced pressure. The residue is suspended in saturated aqueous NaHCO3 and extracted with MeOH / DCM (1:9). The organic layer is dried over Na2SO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give the desired product E-2d.

[0152] Synthesis of E-2e [ka] Experimental procedure for synthesizing IM-19 A stirred solution of IM-18 (10.0 g, 0.044 mol) and TEA (9.1 mL, 0.065 mol) in THF (20.0 mL) is cooled to -20°C and ethyl chloroformate (5.7 g, 0.052 mol) is added. The reaction mixture is stirred at -20°C for 1 h. A freshly prepared solution of diazomethane in diethyl ether (20.0 mL, 0.052 mol) is then added to the reaction mixture and stirring is continued for 2 h at room temperature. The reaction is then quenched using saturated aqueous citric acid. After the mixture is extracted with EtOAc, the organic layer is dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. Purification is carried out by normal phase chromatography (n-hexane / EtOAc 98:2) to give the crude product IM-19. The crude product is used for further synthesis without additional purification.

[0153] Experimental procedure for synthesizing IM-20 The crude starting material IM-19 (4.0 g, 0.016 mol) is dissolved in MeOH (25.0 mL) and TEA (8.8 mL, 0.063 mol) and silver benzoate (720 mg, 0.003 mol) are added. The reaction mixture is then stirred at room temperature for 1 h. The solvent is removed under reduced pressure followed by quenching with a saturated aqueous solution of NaHCO3. Extraction is carried out using EtOAc. The organic layer is dried over Na2SO4 and the solvent is evaporated under reduced pressure. Purification by normal phase chromatography (n-hexane / EtOAc 7:3) gives the crude product IM-20, which is used for further synthesis without additional purification.

[0154] Experimental procedure for synthesizing IM-21 The crude starting material IM-20 (550 mg, 2.14 mmol) is dissolved in THF (25.0 mL) and 1M LAH in THF (3.2 mL, 3.21 mmol) is added. The reaction mixture is stirred at room temperature for 2 h. The reaction is then quenched by the addition of saturated aqueous Na2SO4 and filtered. The filtrate is concentrated under reduced pressure and purified by normal phase chromatography (n-hexane / EtOAc 65:35) to give the crude product IM-21, which is used in further synthesis without additional purification.

[0155] Experimental procedure for synthesizing IM-22 To a solution of crude starting material IM-21 (1.7 g, 7.41 mmol) in DMF (10.0 mL) is added NaH (534 mg, 11.12 mmol) and the reaction mixture is stirred at room temperature for 15 min. Bromomethylbenzene (1.0 mL, 8.16 mmol, 1.1 eq) is added to the reaction mixture and stirring at room temperature is continued for 2 h. The reaction is quenched by addition of a saturated aqueous solution of NH4Cl and extraction is carried out using EtOAc. The organic layer is dried over Na2SO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified successively by normal phase chromatography and reverse phase HPLC (alkaline water / AcCN) to give the pure product IM-22.

[0156] Experimental procedure for synthesizing IM-21 To a stirred solution of IM-22 (3.8 g, 0.012 mol) in MeOH (100.0 mL) is added Pd / C (500 mg, 0.001 mol, 3 mol%) and the reaction mixture is stirred at room temperature under 3 bar hydrogen pressure for 6 h. The reaction mixture is filtered, concentrated under reduced pressure and purified by normal phase chromatography (n-hexane / EtOAc 65:35) to give the desired pure product IM-21. Experimental procedure for the synthesis of E-2e Starting material IM-21 (5.0 g, 21.80 mmol) is dissolved in DCM (50.0 mL) and TFA (3.0 mL, 39.20 mmol) is added to the stirred solution. The reaction mixture is continued to stir at room temperature for 16 h. The solvent is removed under reduced pressure to give the product as a TFA salt E-2e.

[0157] Synthesis of intermediate E-1 Synthesis of E-1a [ka] Experimental procedure for synthesizing IM-23 A stirred solution of TiCl4 (162.7 g, 0.857 mol) in DCM (600.0 mL) is cooled to 0 °C and titanium isopropylate (76.6 mL, 0.257 mol) is added. Stirring at 0 °C is continued for 10 min. DIPEA (166.7 mL, 0.943 mol) is then added and after another 10 min of stirring at 0 °C, IM-1 (100.0 g, 0.429 mol) is added to the reaction mixture. The reaction mixture is then stirred at 0 °C for 1 h. Finally, acrylic acid tert-butyl ester (186.7 mL, 1.286 mol) is added to the reaction mixture and stirring at 0 °C is continued for 6 h. The reaction is quenched by the addition of a saturated aqueous solution of NH4Cl and extraction is carried out using DCM. The organic layer is washed with a saturated aqueous solution of Na2CO3, dried over MgSO4 and filtered. After evaporation of the solvent, the crude product is purified by normal phase chromatography to give the product IM-23.

[0158] Experimental procedure for synthesizing IM-24 A stirred solution of IM-23 (120.0 g, 0.332 mol) in THF (600.0 mL) is cooled to 0° C. and LiBH4 (8.0 g, 0.365 mol) and MeOH (6.0 mL) are added. After addition, the reaction mixture is stirred at room temperature for 2 h. The reaction is quenched with saturated aqueous NH4Cl and extraction is performed using EtOAc. The organic layer is dried over Na2SO4, filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give product IM-24.

[0159] Experimental procedure for synthesizing IM-25 A stirred solution of IM-24 (30.0 g, 0.159 mol) in THF (500.0 mL) is cooled to 0° C. and a 1 M solution of LAH in THF (200.0 mL, 0.200 mol) is carefully added. The reaction mixture is stirred at room temperature for 16 h. The reaction is quenched with 1N aqueous NaOH and water. Then, extraction is performed using EtOAc. The organic layer is dried over Na2SO4, filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography to give the product IM-25.

[0160] Experimental procedure for the synthesis of E-1a To a stirred solution of IM-25 (8.0 g, 67.70 mmol) in DCM (100.0 mL) is added TEA (46.3 mL, 338.48 mmol), DMAP (10.0 mg, 0.08 mmol) and tosyl chloride (38.6 g, 203.09 mmol). The reaction mixture is stirred at room temperature for 4 h. Extraction is performed using water / DCM. The organic layer is dried over Na2SO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (n-hexane / EtOAc 85:15) to give product E-1a.

[0161] Synthesis of intermediate A-7 Experimental procedure for the synthesis of A-7a [ka] Starting materials A-6a (375 mg, 2.21 mmol) and Na2CO3 (563 mg, 5.31 mmol) are dissolved in THF (3.8 mL) and E-2a (525 mg, 2.27 mmol) is added to the reaction mixture. The reaction mixture is stirred at 125° C. for 4 h under microwave irradiation. The solvent is then evaporated under reduced pressure. Water is added to the residue and extraction is carried out using DCM. The combined organic layers are dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. Purification is carried out by reverse phase chromatography (method: prep.HPLC1) to give product A-7a.

[0162] Experimental procedure for the synthesis of A-7b [ka] A-6b (670 mg, 4.75 mmol) and K2CO3 (1.3 g, 9.47 mmol) are dissolved in AcCN (13.5 mL). E-2b (1.0 g, 4.73 mmol) is added and the reaction mixture is stirred at 80° C. for 16 h. After filtering the reaction mixture, the solvent is evaporated under reduced pressure and purification is carried out by reverse phase chromatography (method: prep.HPLC1) to give product A-7b.

[0163] Experimental procedure for the synthesis of A-7c [ka] Starting materials A-6c (45 mg, 0.20 mmol), E-2a (50 mg, 0.21 mmol) and K2CO3 (100 mg, 0.72 mmol) are suspended in THF (0.5 mL) and the reaction mixture is stirred at 80° C. for 1 h. Stirring is continued at room temperature for 16 h. The reaction mixture is then filtered and the solvent is evaporated under reduced pressure. The residue is purified by reverse phase chromatography (method: prep.HPLC1) to give product A-7c.

[0164] The following intermediate A-7 (Table 1) can be accessed in a similar manner starting from different building blocks A-6 and E-2. Intermediate A-7 can be deprotected to give the corresponding deprotected intermediate A-8.

[0165] [Table 3] TIFF0007590996000074.tif234147 TIFF0007590996000075.tif140139

[0166] Synthesis of intermediate A-3 Experimental procedure for the synthesis of A-3a [ka] The starting material A-7c (70 mg, 0.16 mmol) is dissolved in 1,4-dioxane (4.0 mL) and a 1N aqueous solution of HCl (1.0 mL, 1.00 mmol) is added to the solution. The reaction mixture is stirred at room temperature for 19 hours. The solvent is then evaporated under reduced pressure. The residue is purified by reverse phase chromatography (method: prep. HPLC1) to give the deprotected A-8a as an intermediate product (HPLC-MS: (M+H) + =317 / 319, t Ret. =1.0 min, method, VAB).

[0167] A stirred solution of deprotected intermediate A-8a (5.1 g, 15.44 mmol) and TEA (5.5 mL, 39.68 mmol) is cooled to 0° C. and a solution of methanesulfonyl chloride (1.8 mL, 22.16 mmol) in THF (20 mL) is carefully added. The reaction mixture is stirred at 0° C. for 1 h. The reaction mixture is then filtered. Purification is carried out by normal phase chromatography (cyclohexane / EtOAc) to give product A-3a.

[0168] The following intermediate A-3 (Table 2) can be utilized in a similar manner starting from the different building block A-7. [Table 4]

[0169] Synthesis of intermediate A-5 Experimental procedure for the synthesis of A-5a [ka] The starting material A-7a (368 mg, 1.03 mmol) is dissolved in THF (25 mL) and Raney-Nickel (200 mg, 2.25 mmol, 2.2 eq) is added. The reaction mixture is stirred at room temperature under 6 bar hydrogen pressure for 25 h. After filtering the reaction mixture, the solvent is evaporated under reduced pressure to give the intermediate product A-9a (HPLC-MS: (M+H) + =327, t Ret. = 1.6 min, method LCMS3, basisch_1).

[0170] The crude intermediate product A-9a (336 mg, 1.03 mmol) is dissolved in THF (2 mL) and 1-(1H-imidazole-1-carboxamidoyl)-1H-imidazole (250 mg, 1.55 mmol, 1.5 eq) is added. The reaction mixture is stirred at room temperature for 21 h. The solvent is then evaporated under reduced pressure and purification is carried out by reverse phase chromatography (method: prep. HPLC1) to give product A-5a (HPLC-MS: (M+H) + = 420, t Ret. = 1.4 min, method LCMS3, basisch_1).

[0171] The following intermediate A-5 (Table 3) can be utilized in a similar manner starting from the different building block A-7. [Table 5] TIFF0007590996000080.tif78136

[0172] Synthesis of intermediate A-4 Experimental procedure for the synthesis of A-4a [ka] The starting material A-7b (990 mg, 3.36 mmol) is dissolved in MeOH (20.0 mL) and Raney-Nickel (80 mg) is added. The reaction mixture is stirred at room temperature under 5 bar hydrogen pressure for 2 h. After filtration and evaporation of the solvent, the crude intermediate product A-10a was obtained without any further purification (HPLC-MS: (M+H) + =265, t Ret. = 1.0 min, method VAB) for further synthesis.

[0173] The crude intermediate product A-10a (888 mg, 3.36 mmol) is dissolved in tert-BuOH (50.0 mL) and 5M CNBr in AcCN (1.0 mL) is added. The reaction mixture is stirred at 50° C. for 3 h. The reaction mixture is then mixed with a saturated aqueous solution of NaHCO3, stirred for 15 min, and extracted once with DCM. The organic phase is dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure. Purification is carried out by reverse phase chromatography (method: prep.HPLC1) to give product A-4a.

[0174] The following intermediate A-4 (Table 4) can be utilized in a similar manner starting from the different building block A-7. [Table 6] TIFF0007590996000083.tif197143

[0175] Synthesis of intermediate A-2 Experimental procedure for the synthesis of A-2a and A-2b [ka] To a stirred solution of A-1a (209 mg, 0.94 mmol) and E-1a (400 mg, 0.94 mmol) in AcCN (3.0 mL), 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (0.2 mL, 1.59 mmol) is added and the reaction mixture is stirred at room temperature for 16 h. After the reaction mixture is filtered and washed with AcCN, the solvent of the filtrate is evaporated under reduced pressure. The residue is purified by reverse phase chromatography (method: prep.HPLC1) to give the regioisomers A-2a and A-2b in a 1:1 mixture.

[0176] The following intermediate A-2 (Table 5) can be utilized in a similar manner starting from different components A-1 and E-1. [Table 7]

[0177] Synthesis of intermediate B-7 Experimental procedure for the synthesis of B-7a: [ka] The starting materials IM-26 (25.0 g, 0.247 mol) and K2CO3 (75.0 g, 0.543 mol) are dissolved in AcCN (1.0 L) and the solution is cooled to 0° C. SEM-Cl (75.0 g, 0.432 mol) is added dropwise under stirring. The reaction mixture is stirred at room temperature for 1 h. After filtration and purification by normal phase chromatography (DCM / MeOH / NH3 94.5:5:0.5), the desired product IM-27 is obtained (HPLC-MS: (M+H) + =229, t Ret. = 1.0 min, method LCMS3, basisch_1).

[0178] The starting material IM-27 (38.0 g, 0.133 mol) is dissolved in AcCN (570 mL) and the solution is cooled to 0° C. N-iodosuccinimide (32.2 g, 0.136 mol) is then carefully added under stirring. Stirring is continued at 0° C. for 2 h. Then another portion of N-iodosuccinimide (3.2 g, 0.014 mol) is added and stirring is continued at 0° C. for another 30 min. Then the reaction mixture is slowly warmed to room temperature and water is added. Extraction is carried out using DCM. The organic layer is dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (cyclohexane / EtOAc) to give the desired product B-7a (HPLC-MS: (M+H) + =355, t Ret. = 1.2 min, method LCMS3, basisch_1).

[0179] Synthesis of intermediate F-2 Experimental procedure for the synthesis of F-2a: [ka] Bis(pinacolato)diboron (273.3 g, 1.076 mol) is suspended in MTBE (2.5 L) and the mixture is heated to 70° C. The volume of the reaction mixture is reduced by 1 / 3 by distillation and the mixture is cooled to 20° C. (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (8.9 g, 0.013 mol) and 4,4′-di-tert-butyl-2,2′-bipyridyl (7.2 g, 0.027 mol) are then added and the reaction mixture is stirred at room temperature for 15 min. The reaction mixture is then cannulated into a melt of IM-28 (157.0 g, 0.897 mol) and the reaction mixture is stirred at room temperature for 90 h. The solvent is then removed under reduced pressure. The crude oil is stirred in n-hexane (1.0 L) at room temperature for 16 h. The precipitated product is filtered and rinsed with n-hexane. Drying at room temperature for 16 hours gives F-2a.

[0180] The following intermediate F-2 (Table 6) can be utilized in a similar manner starting from different precursors. [Table 8]

[0181] Synthesis of intermediate B-8 Experimental procedure for the synthesis of B-8a: [ka] B-7a (4.0 g, 10.60 mmol), F-2a (4.2 g, 12.72 mmol), tris(dibenzylideneacetone)-dipalladium(0) (243 mg, 0.27 mmol), di(1-adamantyl)-n-butylphosphine (285 mg, 0.80 mmol) and Cs2CO3 (10.4 g, 31.81 mmol) are suspended in toluene (48 mL) and water (12 mL). The reaction mixture is stirred at 65° C. for 5 h. The reaction mixture is then cooled to room temperature and extracted with EtOAc. The organic layer is dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is dissolved in toluene (30 mL) and hexane (300 mL) is added slowly with stirring to cause precipitation of the product. After filtration and washing the precipitate (1 x 5 mL toluene / hexane 1:10, 2 x 5 mL hexane), drying in vacuum gives the product B-8a.

[0182] Experimental procedure for the synthesis of B-8b: [ka] To a solution of B-8a (990 mg, 2.14 mmol) in dioxane (20 mL) is added trimethylboroxine (805 mg, 6.41 mmol), tris(dibenzylideneacetone)dipalladium(0) (49 mg, 0.05 mmol), butyl-di-1-adamantylphosphine (61 mg, 0.16 mmol) and Cs2CO3 (2.1 g, 6.41 mmol). The reaction mixture is stirred at 65° C. for 16 h. After the reaction mixture is filtered and concentrated under reduced pressure, water is added to the residue. Extraction is performed using DCM. The combined organic layers are dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (DCM / MeOH 95:5) to give product B-8b.

[0183] The following intermediate B-8 (Table 7) is accessible in a similar manner starting from different building blocks F-2 and B-7. [Table 9]

[0184] Synthesis of intermediate B-3 Experimental procedure for the synthesis of B-3a: [ka] B-8b (114.6 g, 0.256 mol) is dissolved in THF (360 mL). A solution of NaOH (11.3 g, 0.281 mol) in water (180 mL) is then added and the reaction mixture is stirred at room temperature for 30 min. Then, a 6N aqueous solution of HCl is used to acidify the reaction mixture to pH 5. Filtration of the formed slurry and washing with water gives the crude product, which is dried under vacuum at 50° C. The crude product is redissolved in EtOAc (200 mL) and stirred at 60° C. for 1 h. After cooling to room temperature, n-heptane (150 mL) is added dropwise. Stirring at room temperature is continued for 3 h. Then, filtration, followed by washing of the solid with heptane and drying under vacuum at 50° C. gives the product B-3a.

[0185] The following intermediate B-3 (Table 8) can be utilized in a similar manner starting from different building block B-8. [Table 10]

[0186] Synthesis of intermediate B-1 Experimental procedure for the synthesis of B-1a: [ka] To a stirred solution of B-8b (400 mg, 0.91 mmol) in 1,4-dioxane (2.4 mL) is added a 4 M solution of HCl in 1,4-dioxane (2.3 mL, 9.09 mmol). The reaction mixture is stirred at room temperature for 6 h. The precipitated product is then filtered and washed with 1,4-dioxane (10 mL) and DCM (10 mL). After drying in vacuum, the HCl salt form of the product is obtained. This intermediate is washed with a saturated aqueous solution of Na2CO3 and extracted using DCM to give product B-1a.

[0187] Experimental procedure for the synthesis of B-1b: [ka] To a stirred solution of B-6a (100 mg, 0.43 mmol) in dioxane (3 mL) is added a 2M aqueous solution of K2CO3 (0.3 mL, 0.65 mmol) and Pd dppf (18 mg, 0.02 mmol). The reaction mixture is stirred at 90 °C for 1 h under microwave irradiation. After filtering the reaction mixture and washing with MeOH, the filtrate's solvent is evaporated under reduced pressure. The residue is dissolved in water and extracted with DCM. The combined organic layers are dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. Purification is carried out by normal phase chromatography (DCM / MeOH 50:1) to give the product B-1b.

[0188] The following intermediates B-1 (Table 9) are accessible in a similar manner starting from different building blocks B-6 and E-2, respectively. [Table 11]

[0189] Synthesis of intermediate B-2 Experimental procedure for the synthesis of B-2a: [ka] To a stirred solution of B-1b (89 mg, 0.366 mmol) in AcCN (5 mL) is added 1,5-dibromopentane (E-1b). The reaction mixture is stirred at 110° C. for 8 h, after which the solvent is evaporated under reduced pressure. The residue is dissolved in water and extracted with DCM. The organic layer is dried over MgSO4, filtered, and the solvent is removed under vacuum. The crude product is purified by normal phase chromatography (cyclohexane / EtOAc 7:3) to give product B-2a.

[0190] Experimental procedure for synthesizing B-2p: [ka] To a stirred solution of B-1h (1500 mg, 5.81 mmol) in AcCN (30 mL) and DMF (30 mL) is added K2CO3 (1.20 g, 8.71 mmol) and cooled to 0 °C. To this reaction mixture is added a solution of E-1a (5.0 g, 11.6 mmol) and the mixture is stirred at this temperature for 16 h. The solvent is evaporated under reduced pressure, water is added and the mixture is extracted with DCM. The collected organic phase is dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude product is purified by flash chromatography with DCM:MeOH (50:1) to give B-2p.

[0191] The following intermediate B-2 (Table 10) can be utilized in a similar manner starting from different components B-1 and E-1. [Table 12] TIFF0007590996000100.tif223145 TIFF0007590996000101.tif104140

[0192] Synthesis of intermediate C-3 Experimental procedure for the synthesis of C-3a: [ka] Starting materials A-3a (3.1 g, 7.34 mmol), B-1a (2.3 g, 8.84 mmol) and K2CO3 (3.1 g, 22.01 mmol) are dissolved in AcCN (208 mL) and the reaction mixture is stirred under reflux for 12 h. The reaction mixture is then filtered and washed with AcCN. The solvent is evaporated from the filtrate under reduced pressure. The residue is purified by normal phase chromatography (cyclohexane / EtOAc) to give product C-3a.

[0193] The following intermediate C-3 (Table 11) is accessible in a similar manner starting from different building blocks A-3 and B-1. [Table 13] TIFF0007590996000104.tif73134

[0194] Synthesis of intermediates C-1 and C-4 Experimental procedure for the synthesis of C-1a: [ka] To a stirred solution of starting material B-2a (60 mg, 0.15 mmol) in AcCN (1 mL) is added a suspension of K2CO3 (40 mg, 0.30 mmol) and A-1b (30 mg, 0.22 mmol) in AcCN (1 mL). The reaction mixture is stirred at 90 °C for 16 h, then filtered and concentrated under vacuum. The residue is redissolved in water and extracted with DCM. The organic layer is dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by normal phase chromatography (DCM / MeOH 50:1) to give the desired product C-1a.

[0195] Experimental procedure for the synthesis of C-1b and C-1c [ka] A 1:1 mixture of regioisomers A-2a and A-2b (132 mg, 0.28 mmol), starting material B-1a (70 mg, 0.28 mmol) and K2CO3 (59 mg, 0.43 mmol) are dissolved in AcCN (1 mL). The reaction mixture is stirred at 80° C. for 48 h. The reaction mixture is then filtered and the precipitate is washed with AcCN. The solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (method: prep.HPLC1) to give a 1:1 mixture of ester-regioisomers C-1b and C-1c.

[0196] Experimental procedure for the synthesis of C-4a and C-4b: [ka] The obtained intermediates C-1b and C-1c are dissolved in THF (2 mL), aqueous LiOH (0.5 mL, 50 mg, 2.1 mmol) is added and the mixture is stirred at 50 °C for 4 h. The organic solvent is evaporated and the aqueous phase is adjusted to a pH value of 6-7. The precipitate is collected and dried to give C-4a and C-4b.

[0197] Experimental procedure for the synthesis of C-1d and C-4c: [ka] The starting material C-3b (3.0 g, 5.36 mmol) is dissolved in a mixture of THF (1000 mL) and cyclohexane (1000 mL). An aqueous slurry of Raney-Nickel sponge (50%) is then added and the reaction mixture is stirred under 5 bar hydrogen pressure for 6 h. The reaction mixture is then filtered and the solvent is evaporated under reduced pressure. The crude product C-5a is dissolved in toluene, evaporated to dryness again and used in the subsequent reaction without further purification.

[0198] The intermediate product C-5a (2.7 g, 5.23 mmol) is dissolved in tert-butanol (20 mL). Then, 3M cyanogen bromide in DCM (2.6 mL, 7.84 mmol) is added and the reaction mixture is stirred at 50° C. for 3 h. The reaction mixture is then diluted with DCM and the reaction is quenched with an aqueous solution of NaHCO3. After extraction with DCM, the organic phase is dried over MgSO4 and filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (method: prep.HPLC1) to give the ester C-1d, which is dissolved in THF and treated with 1M aqueous NaOH (400 μL). After 1 h, the solvent is evaporated to give the product C-4c.

[0199] The following intermediates C-1 and C-4 (Table 12) are accessible in a similar manner starting from different building blocks A-1, A-2, B-1, B-2 and C-3. [Table 14] TIFF0007590996000110.tif218143 TIFF0007590996000111.tif239148 TIFF0007590996000112.tif229146 TIFF0007590996000113.tif213143 TIFF0007590996000114.tif229146 Synthesis of intermediate C-2

[0200] Experimental procedure for the synthesis of C-2a: [ka] Starting material B-3a (1.2 g, 3.42 mmol) is dissolved in 1,4-dioxane (33 mL). TEA (2.9 mL) and HATU (1.6 g, 4.12 mmol) are added to the solution, which is stirred at room temperature for 20 min. A-4j (1.1 g, 3.42 mmol) is then added, and the reaction mixture is stirred at room temperature for 48 h. Then, extraction is performed using DCM / water. The organic layer is dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure to give the crude intermediate product C-6a, which is used for further synthesis without any additional purification steps.

[0201] The crude intermediate product C-6a (512 mg, 0.42 mmol) is dissolved in EtOH (10 mL) and a 4 M solution of HCl in 1,4-dioxane (5.0 mL, 20.00 mmol) is added to the solution. The reaction mixture is stirred at room temperature for 16 h. A saturated aqueous solution of NaHCO3 is then added and the reaction mixture is extracted twice with DCM. The combined organic layers are dried over MgSO4, filtered and the solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (prep. HPLC1) to give product C-2a.

[0202] Experimental procedure for the synthesis of C-2b: [ka] Starting materials B-3a (1.0 g, 2.75 mmol), HATU (1.1 g, 2.84 mmol) and DIPEA (2.0 mL, 11.76 mmol) are dissolved in 1,4-dioxane (20 mL) and the reaction mixture is stirred at 55° C. for 30 min. Then, A-5a (1.0 g, 2.38 mmol) is added to the reaction mixture and stirring is continued at 55° C. for 1 h, followed by stirring at room temperature for 48 h. The reaction mixture is then concentrated under reduced pressure and the residue is purified by reverse phase chromatography (method: prep.HPLC1) to give intermediate product C-6b.

[0203] The intermediate product C-6b (633 mg, 0.91 mmol) is dissolved in THF (20 mL) and a 1 M solution of TBAF in THF (3.5 mL, 3.50 mmol) is added to the solution. The reaction mixture is stirred at room temperature for 72 h. Stirring is continued at 50° C. for 72 h. Acetone is then added to the reaction mixture and the solvent is evaporated under reduced pressure. The solid is suspended in AcCN and the solid material is collected by filtration to give product C-2b.

[0204] The following intermediate C-2 (Table 13) can be utilized in a similar manner starting from different building blocks A-4, A-5 and B-3. [Table 15] TIFF0007590996000118.tif203142 TIFF0007590996000119.tif203143 TIFF0007590996000120.tif197143 TIFF0007590996000121.tif62127

[0205] Preparation of Compound (I) According to the Invention Experimental Procedure for the Synthesis of I-003 (Method A) [ka] The starting material C-1s (34 mg, 0.07 mmol) is dissolved in DMSO (0.8 mL), 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (0.02 mL, 0.13 mmol) is added, and the reaction mixture is stirred for 48 h at 80° C. The reaction mixture is then filtered and purified by reverse phase chromatography (method: prep.HPLC1) to give the product I-003.

[0206] Experimental Procedure for the Synthesis of I-057 and I-020 (Method A') [ka] C-4c (227 mg, 0.421 mmol) and DIPEA (0.37 mL, 2.10 mmol) are dissolved in dioxane (5 mL) and the reaction mixture is stirred for 10 min at 25° C. Then HATU (240 mg, 0.63 mmol) is added and stirring of the reaction mixture at 25° C. is continued for 2 h. The solvent is evaporated under reduced pressure and the crude product is purified by normal phase chromatography (EtOAc / MeOH 90:10) to give I-057.

[0207] I-057 (50 mg, 0.096 mmol) is dissolved in dioxane (750 μL) and N-methylpiperazine (0.042 mL, 0.38 mmol) and methanesulfonato(2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (8.6 mg, 0.01 mmol) are added. The reaction mixture is flushed with argon and LiHMDS (0.28 mL, 0.28 mmol) is added slowly at room temperature. The reaction mixture is then stirred at 65° C. for 30 min. The solvent is evaporated under reduced pressure and the crude product is purified by reverse phase chromatography (method: prep.HPLC1) to give product I-020.

[0208] Experimental Procedure for the Synthesis of I-012 (Method A) [ka] B-2b (1200 mg, 1.88 mmol) is dissolved in AcCN (10 mL) and K2CO3 (393 mg, 2.82 mmol) and A-1b (275 mg, 2.07 mol) are added. The reaction mixture is stirred at 100 °C for 4 days. The solvent is evaporated under reduced pressure, water is added and the mixture is extracted with DCM. The collected organic phases are dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude product is purified by column chromatography (40 g SiO2, cyclohexane / EtOAc 1:1) to give D-1a (HPLC-MS: (M+H) + =567.0, t Ret. = 1.86 min, method LCMS3, basisch_1).

[0209] Intermediate D-1a is dissolved in THF (2 mL) and TBAF (1M in THF, 0.200 mL, 0.200 mmol) is added. The reaction mixture is stirred at 25° C. for 18 h. The solvent is evaporated under reduced pressure, water is added and the mixture is extracted with DCM. The collected organic phases are dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (method: prep.HPLC1) to give product I-012.

[0210] Experimental procedure for the synthesis of I-001 (Synthetic Method B) [ka] C-2a (50 mg, 0.12 mmol) is dissolved in THF (4.0 mL) and triphenylphosphine (130 mg, 0.47 mmol) is added to the solution. After stirring the reaction mixture at room temperature for 20 min, diisopropyl azodicarboxylate (0.1 mL, 0.48 mmol) is added to the reaction mixture. The reaction is then stirred at room temperature for 1 h. Extraction is then performed using DCM / water. The organic layer is dried over MgSO4, filtered, and the solvent is evaporated under reduced pressure. The crude product is purified by reverse phase chromatography (method: prep.HPLC1) to give product I-001.

[0211] Experimental procedure for the synthesis of I-006 (Synthetic Method B) [ka] C-2d (25 mg, 0.052 mmol) is dissolved in dry AcCN (3 mL) and K2CO3 (43 mg, 0.31 mmol) is added. The mixture is stirred at 90 °C for 16 h. The reaction mixture is filtered and purified by reverse phase chromatography (prep. HPLC 1 method) to give I-006.

[0212] Experimental procedure for the synthesis of I-014 [ka] I-013 (50 mg, 0.11 mmol), benzoic acid (30 mg, 0.24 mmol) and triphenylphosphine (100 mg, 0.36 mmol) are dissolved in THF (5 mL) and diisopropyl azodicarboxylate (0.09 mL, 0.43 mmol) is added. The reaction mixture is shaken at room temperature for 16 h. The solvent is evaporated under reduced pressure and the crude product is purified using the prep. HPLC method to give intermediate D-1b (HPLC-MS: (M+H) + =551, t Ret. =0.83 min, method VAB).

[0213] Intermediate D-1b (43 mg, 0.074 mmol) is dissolved in 1,4-dioxane (0.5 mL) and LiOH (1 M solution, 0.5 mL) is added. The reaction is shaken at 25° C. for 3 h. The solvent is evaporated under reduced pressure and the crude product is purified using prep. HPLC method to give I-014.

[0214] Experimental procedure for the synthesis of I-023 (Synthetic Method B) [ka] C-2k (160 mg, 0.35 mmol) is dissolved in dry AcCN and K2CO3 (97 mg, 0.70 mmol) is added. Then p-toluenesulfonyl chloride (80 mg, 0.42 mmol) is added. The reaction mixture is stirred at room temperature for 18 h. The solvent is evaporated under reduced pressure, water is added and the mixture is extracted with DCM. The collected organic phases are dried over Na2SO4 and the solvent is evaporated under reduced pressure to give intermediate C-2z (HPLC-MS: (M+H) + =611, t Ret. =0.65 minutes, Method 2_FEC_PN).

[0215] Intermediate C-2z (90 mg, 0.15 mmol) is dissolved in dry THF and K2CO3 (41 mg, 0.30 mmol) is added. The reaction mixture is stirred at 90 °C for 3 days. The solvent is evaporated under reduced pressure, water is added and the mixture is extracted with DCM. The collected organic phases are dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude product is purified by flash chromatography with DCM:MeOH (10:1) to give I-023.

[0216] The following compounds (I) (Table 14) can be utilized in a similar manner starting from the different components A-1, B-2, C-1 and C-2 or by derivatization of the initially obtained compounds (I). [Table 16] TIFF0007590996000130.tif213157 TIFF0007590996000131.tif208158 TIFF0007590996000132.tif208157 TIFF0007590996000133.tif203159 TIFF0007590996000134.tif218160 TIFF0007590996000135.tif223161 The following examples describe the biological activity of the compounds according to the invention without, however, restricting the invention to these examples.

[0217] Biochemical EGFR inhibition assay First, the inhibitory effect of the compounds according to the invention is measured in a biochemical assay measuring the phosphorylation activity of the EGFR enzymatic form on a poly-GT substrate in the presence of different concentrations of ATP (5 μM and 100 μM final assay concentrations). The following enzymatic forms of EGFR are representative examples that may be used in these assays at the concentrations given: EGFR wt (Life technologies, PV4190), final assay concentration 1.5 nM EGFR(d746-750 T790M C797S) (SignalChem, E10-12UG), final assay concentration 15 nM EGFR (mutant) 695-1022, T790M, C797S, L858R (autologous prep), final assay concentration 3nM Test compounds dissolved in DMSO are dispensed onto assay plates (Proxiplate 384 PLUS, white, PerkinElmer, 6008289) using an Access Labcyte workstation equipped with a Labcyte Echo 55x. 150 nL of compound solution is transferred from a 10 mM DMSO compound stock solution for the selected highest assay concentration of 100 μM. A series of 5-fold dilutions, 11 per compound, are transferred to the assay plate and compound dilutions are tested in duplicate. DMSO is added as backfill to a total volume of 150 nL. The assay is run on a fully automated robotic system.

[0218] Distribute 5 μL of EGFR enzyme forms in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) into columns 1-23, but add 5 μL of ATP and ULight-Poly-GT substrate (PerkinElmer, TRF0100-M) mix in assay buffer to all wells (final assay concentration of ULight-Poly-GT substrate 200 nM). Each of the different EGFR enzyme form assays is available at low ATP levels (final assay concentration 5 μM) and high ATP levels (final assay concentration 100 μM). After 90 min incubation at room temperature, add 5 μL EDTA (final assay concentration 50 mM) and LANCE Eu-anti-P-Tyr (PT66) antibody (PerkinElmer, AD0069) (final assay concentration 6 nM) mix to stop the reaction and initiate antibody binding. After a further 60 min incubation at room temperature, the signal is measured on a PerkinElmer Envision HTS Multilabel Reader using TR-FRET LANCE Ultra specs from PerkinElmer (wavelengths used: excitation 320 nm, emission 1 665 nm, emission 2 615 nm). Each plate contains 16 wells of negative control (DMSO diluted instead of test compound, w / o EGFR enzyme form, column 23) and 16 wells of positive control (DMSO diluted instead of test compound, w / o EGFR enzyme form, column 24). The negative and positive control values ​​are used for normalization and IC 50 Values ​​are calculated and analyzed using a four-parameter logistic model.

[0219] These biochemical EGFR enzymatic compound dose-response assays quantitate kinase activity via phosphorylation of a tagged poly-GT substrate. The results of the assays are expressed as IC 50 The IC value reported for a given compound is 50 The lower the value, the more potently the compound inhibits the kinase activity of the EGFR enzyme on the poly-GT substrate. Table 15 shows the ICs of the compounds according to the invention generated in the corresponding biochemical assays described above. 50 Contains data. [Table 17]

[0220] Generation of Ba / F3 cell model and proliferation assay Ba / F3 cells were ordered from DSMZ (ACC300, Lot17) and grown in RPMI-1640 (ATCC 30-2001) + 10% FCS + 10ng / ml IL-3 at 37°C in a 5% CO2 atmosphere. Plasmids containing EGFR mutants were obtained from GeneScript. To generate an EGFR-dependent Ba / F3 model, Ba / F3 cells were transduced with retroviruses containing vectors with EGFR isoforms. Platinum-E cells (Cell Biolabs) were used for packaging the retroviruses. Retroviruses were added to Ba / F3 cells. To ensure infection, 4μg / mL polybrene was added and cells were spinfected. Infection efficiency was confirmed by measuring GFP-positive cells using a cell analyzer. Cells with an infection efficiency of 10%-20% were further cultured and puromycin selection was started at 1μg / mL. As a control, Ba / F3 parental cells were used to demonstrate the selection condition. Selection was considered successful if the culture of parental Ba / F3 cells died. To assess the transforming potential of EGFR mutations, the growth medium was not supplemented with IL-3. Ba / F3 cells carrying an empty vector were used as a control. In Ba / F3 cells carrying wild-type EGFR, known to be dependent on EGF ligand, a switch from IL-3 to EGF was made. Puromycin was removed approximately 10 days before the experiment was performed. For proliferation assays (data in Table 13), Ba / F3 cells were plated in 96-well plates at 5×10 3Cells / 100μL were seeded. Compounds were added by using HP D3000 digital dispenser. All treatments were performed in technical triplicate. Treated cells were incubated at 37℃, 5%CO2 for 72 hours. CellTiter-Glo® fluorescent cell viability assay (Promega) was performed and chemiluminescence was measured by using multi-label plate reader VICTOR X4. Raw data was imported into and analyzed with Boehringer Ingelheim's proprietary software MegaLab (curve fitting based on the program PRISM, GraphPad Inc.).

[0221] [Table 18]

[0222] [Table 19]

[0223] [Table 20]

[0224] [Table 21]

[0225] pEGFR assay This assay is used to quantify the phosphorylation of EGFR at Tyr1068 and to measure the inhibitory effect of compounds on the transgenic EGFR del19 T790M C797S protein in Ba / F3 cells. Mouse Ba / F3 cells were grown in RPMI-1640 (ATCC 30-2001) + 10% FCS + 10ng / mL IL-3 at 37°C in a 5% CO2 atmosphere and transduced with a retroviral vector encoding EGFR del19 T790M C797S. Transduced cells were selected using puromycin. After selection, IL-3 was withdrawn and IL-3-independent cells were cultured. p-EGFR Tyr1068 was determined using the AlphaScreen Surefire pEGF Receptor (Tyr1068) Assay (PerkinElmer, TGRERS). For the assay, Ba / F3 EGFR del19 T790M C797S cells were seeded in DMEM medium with 10% FCS. 60 nL compound dilutions were added to each well of a Greiner TC 384 plate using the Echo platform. Then, 60.000 cells / well in 60 μL were added. Cells were incubated with compounds for 4 hours at 37°C. After centrifugation and removal of the medium supernatant, 20 μL of 1.6x lysis buffer and protease inhibitors from the TGR / Perkin Elmer kit were added. The mixture was incubated for 20 minutes at room temperature with shaking (700 rpm). After centrifugation, 4 μL of lysate was transferred to Proxiplates. 5 μL of acceptor mix (Activation Buffer diluted 1:25 in combined Reaction Buffer 1 and Reaction Buffer 2 (TGRERS Assay Kit, PerkinElmer) and Protein A Acceptor Beads 6760137 at 1:50) was added to each well. The plate was shaken for 1 min (1400 rpm) and incubated in the dark at room temperature for 2 h. 3 μL of donor mix (AlphaScreen Streptavidin Coated Donor Beads (6760002, PerkinElmer) diluted 1:50 in Dilution Buffer (TGRERS Assay Kit, PerkinElmer) was added to each well.The plate was shaken (1400 rpm) for 1 min and incubated in the dark at room temperature for 2 h. The plate was then analyzed using the Envision reader platform. The results were calculated in the following way: the ratio of the test compound value and the negative control (DMSO) value was calculated. IC. 50 Values ​​are calculated using a four-parameter logistic model using MEGASTAR IC 50 The application calculates from these values.

[0226] This cellular phospho-EGFR (pEGFR) compound dose-response assay quantifies phosphorylation of EGFR at Tyr1068 in Ba / F3 cells expressing the EGFR variant del19 T790M C797S. Results of the assay are expressed as IC 50 The IC of pEGFR reported for a given compound is shown as a 1:1 ratio (see Table 14). 50 The lower the value, the more potently the compound inhibits the EGFR del19 T790M C797S target protein in Ba / F3 cells. Yet another aspect of the present invention may be as follows. [1] A compound of formula (I) or a salt thereof. [ka] (In the formula, [ka] is selected from the group consisting of phenylene and 5- to 6-membered heteroarylene; p is selected from the group consisting of 0, 1, 2 and 3; Each R 1 is R a1 and R b1 are independently selected from the group consisting of: R a1 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R b1 and / or R c1 may be substituted with Each R b1 -OR c1 , -NR c1 R c1 , halogen, -CN, -C(O)R c1 , -C(O)OR c1 , -C(O)NR c1 R c1 , -S(O) 2 R c1 , -S(O) 2 NR c1 R c1 , -NHC(O)R c1 , -N(C 1-4 Alkyl)C(O)R c1 , -NHC(O)OR c1 , -N(C 1-4 Alkyl)C(O)OR c1 and the divalent substituent =O, Each R c1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Cycloalkenyl, 3-10 membered heterocyclyl, C 6-10 All aryl and 5- to 10-membered heteroaryl groups are each selected from one or more of the same or different R d1 and / or R e1 may be substituted with Each R d1 -OR e1 , -NR e1 R e1 , halogen, -CN, -C(O)R e1 , -C(O)OR e1 , -C(O)NR e1 R e1 , -S(O) 2 R e1 , -S(O) 2 NR e1 R e1 , -NHC(O)R e1 , -N(C 1-4 Alkyl)C(O)R e1 , -NHC(O)OR e1 , -N(C 1-4 Alkyl)C(O)OR e1 and the divalent substituent =O, Each R e1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 cycloalkyl, C 4-10 Cycloalkenyl, C 1-4 3-10 membered heterocyclyl optionally substituted with alkyl, C 1-4 Alkoxy-C1-4 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl and (C 1-4 Alkyl) 2 Amino-C 1-4 independently selected from the group consisting of alkyl,

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

[10] above, 〔12〕R 3 But hydrogen, C 1-4 The compound or salt according to any one of the above [1] to

[12] , wherein the alkyl group is selected from the group consisting of alkyl, halogen and -CN.

[13] L is a linear C 3-7 Alkylene, such a linear C 3-7 One or two methylene groups in alkylene -CH 2 - is oxygen, -NH- and -N(C 1-4 alkyl)-, Such a linear chain is represented by the carbon atom C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; One carbon atom, two carbon atoms or one carbon atom and one nitrogen atom in such a straight chain may be C 1-5 It may be bridged with an alkylene, such bridge C 1-5 One methylene group in alkylene -CH 2 - is replaced by oxygen, C 3-6 The compound or salt according to any one of the above [1] to

[12] , which may form a carbocyclic ring or a 3- to 6-membered nitrogen- and / or oxygen-containing heterocyclic ring.

[14] L is a linear C 3-7 is alkylene, Linear C 3-7 Alkylene is C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; Linear C 3-7 One or two carbon atoms in the alkylene are C 1-5 Bridged with alkylene to form C 3-6 The compound or salt according to any one of the above [1] to

[13] , which may form a carbocyclic ring.

[15] L is a linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 alkylene; Linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 Alkylene is C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, halogen and hydroxy; Such a linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 One or two carbon atoms in the alkylene are C 1-5 Bridged with alkylene to form C 3-6 The compound or salt according to any one of the above [1] to

[14] , which may form a carbocyclic ring.

[16] The compound according to any one of the above [1] to

[15] , or a pharma- ceutical acceptable salt thereof, for use as a medicine.

[17] The compound according to any one of [1] to

[15] above, or a pharma- ceutical acceptable salt thereof, for use in the treatment and / or prevention of a disease and / or condition in which inhibition of mutant EGFR would be of therapeutic benefit.

[18] The compound according to any one of the above [1] to

[15] , or a pharma- ceutical acceptable salt thereof, for use in treating and / or preventing cancer.

[19] The compound for use according to any one of

[16] to

[18] above, or a pharma- ceutical acceptable salt thereof, wherein the compound is administered before, after, or together with at least one other pharmacologically active substance.

[20] The compound for use according to any one of

[16] to

[18] above, or a pharma- ceutical acceptable salt thereof, wherein the compound is administered in combination with at least one other pharmacologically active substance.

[21] A method for treating and / or preventing a disease and / or condition for which inhibition of mutant EGFR would be of therapeutic benefit, comprising the step of administering to a human a therapeutically effective amount of a compound according to any one of [1] to

[15] above or a pharmacologic acceptable salt thereof.

[22] A method for treating and / or preventing cancer, comprising the step of administering to a human a therapeutically effective amount of a compound according to any one of [1] to

[15] above, or a pharma- ceutical acceptable salt thereof.

[23] The method according to any one of

[21] and

[22] above, wherein the compound or a pharma- ceutical acceptable salt thereof is administered before, after, or together with at least one other pharmacologically active substance.

[24] The method according to any one of

[21] and

[22] above, wherein the compound or a pharma- ceutical acceptable salt thereof is administered in combination with a therapeutically effective amount of at least one other pharmacologically active substance.

[25] The compound for use according to any one of

[18] to

[20] above or a pharma- ceutical acceptable salt thereof, or the method according to any one of

[22] to

[24] above, wherein the cancer is selected from the group consisting of lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial cancer, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer and mesothelioma, including metastasis (particularly brain metastasis) of all of the cancers listed.

[26] A pharmaceutical composition comprising the compound according to any one of [1] to

[15] above, or a pharma- ceutical acceptable salt thereof, and one or more pharma- ceutical acceptable excipients.

[27] A pharmaceutical preparation comprising the compound according to any one of [1] to

[15] above, or a pharma- ceutical acceptable salt thereof, and at least one (preferably one) other pharmacologically active substance.

Claims

1. A compound of formula (I) or a salt thereof. [Formula 1] (In the formula, [chemical 2] teeth, [C3] is selected from the group consisting of p is selected from the group consisting of 0, 1, 2 and 3; Each R 1 is R a1 and R b1 are independently selected from the group consisting of R a1 is C 1-6 is selected from the group consisting of alkyl and 3- to 10-membered heterocyclyl; 1-6 All of the alkyl and 3- to 10-membered heterocyclyl groups may be one or more of the same or different R b1 and / or R c1 may be substituted with Each R b1 is -OR c1 , -NR c1 R c1 , halogen, -CN, -C(O)R c1 , -C(O)OR c1 , -C(O)NR c1 R c1 and the divalent substituent =O; Each R c1 is hydrogen, C 1-6 Alkyl, C 3-10 independently selected from the group consisting of cycloalkyl and 3- to 10-membered heterocyclyl; 1-6 Alkyl, C 3-10 Cycloalkyl and 3- to 10-membered heterocyclyl may each be one or more of the same or different R d1 and / or R e1 may be substituted with Each R d1 is -OR e1 , -NR e1 R e1 , halogen, -CN, -C(O)R e1 , -C(O)OR e1 , -C(O)NR e1 R e1 and the divalent substituent =O; Each R e1 is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, C 1-4 3- to 10-membered heterocyclyl optionally substituted with alkyl, C 1-4 Alkoxy-C 1-4 Alkyl and (C 1-4 Alkyl) 2 Amino-C 1-4 independently selected from the group consisting of alkyl, [C4] teeth, [C5] is selected from the group consisting of q is selected from the group consisting of 0, 1 and 2; Each R 2 is C 1-4 Alkyl, C 1-4 Haloalkyl, -CN, C 1-4 Alkoxy, C 1-4 independently selected from the group consisting of haloalkoxy and halogen; R 3 is hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen, -CN, -NH 2 , -NH(C 1-4 alkyl) and -N(C 1-4 Alkyl) 2 is selected from the group consisting of L is a linear C 3-7 is alkylene, The linear C 3-7 alkylene is 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, aryl, aryloxy, and hydroxy; One or two carbon atoms in the linear C 3-7 alkylene are 1-5 Bridged with alkylene, C 3-6 may form a carbocyclic ring)

2. p is 1, Each R 1 But halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heterocyclyl-C with 5- to 7-membered heterocyclyl optionally substituted with alkyl 1-4 Alkoxy, C 1-4 Heterocyclyl-C with 5- to 7-membered heterocyclyl optionally substituted with alkyl 1-4 Alkyl, C 1-4 5- to 7-membered heterocyclyl optionally substituted by alkyl, (C 1-4 Alkyl) 2 N-C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl) 2 , C 1-4 -C(O)-heterocyclyl and -C(O)O-C, optionally substituted with alkyl, 1-4 2. The compound or salt of claim 1, wherein the compound or salt is selected from the group consisting of alkyl.

3. The compound or salt of claim 1, wherein p is 0.

4.

6. but, [C7] That is, 3. A compound or salt according to claim 1 or 2.

5.

8. but, [C9] That is, 3. A compound or salt according to claim 1 or 2.

6. The compound or salt according to claim 1, wherein q is 0.

7. q is 1, R 2 But, C 1-4 The compound or salt of any one of claims 1 to 5, wherein the radical is selected from the group consisting of alkyl and halogen.

8. R 3 is hydrogen, C 1-4 The compound or salt of any one of claims 1 to 7, wherein the group is selected from the group consisting of alkyl, halogen and -CN.

9. L is a linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 alkylene; Linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 The alkylene is C 1-4 may be substituted with one or more identical or different substituents selected from the group consisting of alkyl, aryl, aryloxy, and hydroxy; Such a linear C 4 Alkylene, linear C 5 Alkylene, linear C 6 Alkylene and linear C 7 One or two carbon atoms in the alkylene are 1-5 Bridged with alkylene to form C 3-6 The compound or salt according to any one of claims 1 to 8, which optionally forms a carbocyclic ring.

10. 10. The compound according to any one of claims 1 to 9, selected from the group consisting of: [C10] [ka] [ka] [ka]

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof.

12. 12. A pharmaceutical composition according to claim 11 for use in the treatment and / or prevention of diseases and / or conditions in which inhibition of mutant EGFR would be of therapeutic benefit.

13. 13. A pharmaceutical composition according to claim 11 or 12 for use in the treatment and / or prevention of cancer.

14. A pharmaceutical composition according to any one of claims 11 to 13 for use in a method in which the compound is administered before, after or together with at least one other pharmacologically active agent.

15. A pharmaceutical composition according to any one of claims 11 to 13 for use in a method in which the compound is administered in combination with at least one other pharmacologically active substance.

16. The pharmaceutical composition according to any one of claims 13 to 15, wherein the cancer is selected from the group consisting of lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial cancer, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer and mesothelioma, including metastases (particularly brain metastases) of all the cancers listed.

17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.

18. A pharmaceutical preparation comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, and at least one (preferably one) other pharmacologically active substance.

Citation Information

Patent Citations

  • Compounds and compositions for modulating EGFR activity

    JP2015518894A

  • Compounds and compositions for modulating EGFR activity

    JP2015518895A

  • Macrocyclic pyridazinone derivatives

    JP2016507539A